<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40013154</article-id><article-id pub-id-type="pmc">PMC11862915</article-id><article-id pub-id-type="doi">10.3389/fimmu.2025.1546474</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Sepsis subphenotypes: bridging the gaps in sepsis treatment strategies</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xue</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2924727"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Wei</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1434996"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Huan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2115038"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Liao</surname><given-names>Xuelian</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1187032"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Critical Care Medicine, West China Hospital, Sichuan University</institution>, <addr-line>Chengdu, Sichuan</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Institute of Critical Care Medicine, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University</institution>, <addr-line>Chengdu, Sichuan</addr-line>, <country>China</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Department of Critical Care Medicine, West China Tianfu Hospital, Sichuan University</institution>, <addr-line>Chengdu, Sichuan</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Daolin Tang, University of Texas Southwestern Medical Center, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Xiaopei Shen, Fujian Medical University, China</p><p>Sebastian Isac, Carol Davila University of Medicine and Pharmacy, Romania</p><p>Tamer A. Addissouky, University of Menoufia, Egypt</p></fn><corresp id="fn001">*Correspondence: Xuelian Liao, <email xlink:href="mailto:liaoxuelian@scu.edu.cn">liaoxuelian@scu.edu.cn</email>
</corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1546474</elocation-id><history><date date-type="received"><day>17</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>20</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Zhang, Zhang, Zhang and Liao</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Zhang, Zhang, Zhang and Liao</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Sepsis, a heterogeneous illness produced by a dysregulated host response to infection, remains a severe mortality risk. Recent discoveries in sepsis research have stressed phenotyping as a feasible strategy for tackling heterogeneity and enhancing therapy precision. Sepsis phenotyping has moved from traditional stratifications based on severity and prognosis to dynamic, phenotype-driven therapeutic options. This review covers recent progress in connecting sepsis subgroups to personalized treatments, with a focus on phenotype-based therapeutic predictions and decision-support systems. Despite ongoing challenges, such as standardizing phenotyping frameworks and incorporating findings into clinical practice, this topic has enormous promise. By investigating phenotypic variation in therapy responses, we hope to uncover new biomarkers and phenotype-driven therapeutic solutions, laying the groundwork for more effective therapies and, ultimately improving patient outcomes.</p></abstract><kwd-group><kwd>sepsis heterogeneity</kwd><kwd>phenotyping</kwd><kwd>personalized therapy</kwd><kwd>phenotype-driven treatment</kwd><kwd>biomarkers</kwd><kwd>therapeutic target identification</kwd></kwd-group><funding-group><funding-statement>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National key research and development plan of China (grant number 2022YFC2009804).</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="3"/><equation-count count="0"/><ref-count count="167"/><page-count count="18"/><word-count count="8348"/></counts><custom-meta-group><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Inflammation</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>Sepsis is a primary cause of mortality among critically sick patients worldwide, accounting for approximately 49 million cases and 11 million deaths each year, representing nearly 20% of all deaths worldwide (<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B3" ref-type="bibr">3</xref>). It results from an anomalous immunological response to infection that precipitates organ failure (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B4" ref-type="bibr">4</xref>). Sepsis exhibits high clinical heterogeneity, making the discovery of effective treatments exceedingly challenging (<xref rid="B5" ref-type="bibr">5</xref>). Despite advances in understanding the cellular and molecular causes of sepsis, its complicated pathophysiology remains a problem (<xref rid="B6" ref-type="bibr">6</xref>). This heterogeneity arises from diverse pathogens, infection sites, and host immune responses that interact intricately to shape the clinical presentation (<xref rid="B7" ref-type="bibr">7</xref>&#x02013;<xref rid="B11" ref-type="bibr">11</xref>). The phenotypical variability in sepsis is reflected across various clinical manifestation. Hemodynamic alterations, including blood pressure, cardiac output, and systemic vascular resistance, are prevalent indicators of sepsis-induced circulatory dysfunction (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>). Coagulation diseases, including disseminated intravascular coagulation (DIC), platelet failure, and microthrombosis, intensify organ damage (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). Neurological manifestations encompass sepsis-associated encephalopathy and delirium, reflecting both direct and indirect impacts on the central nervous system (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>). Metabolic instability, including hyperlactatemia and mitochondrial dysfunction, underscores the systemic nature of sepsis (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>). Respiratory issues, especially acute respiratory distress syndrome (ARDS) and hypoxemia, often predominate the clinical trajectory, however other systems, including renal and hepatic, exhibit varied responses based on the patient&#x02019;s phenotype (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B20" ref-type="bibr">20</xref>&#x02013;<xref rid="B22" ref-type="bibr">22</xref>).</p><p>Given this multifaceted heterogeneity, understanding how these clinical factors interplay to shape sepsis phenotypes is essential. Recent advancements in big data methodologies, artificial intelligence, and high-throughput multi-omics data, along with disease phenotyping, offer novel pathways for enhancing the comprehension of sepsis and formulating more personalized treatment strategies (<xref rid="B23" ref-type="bibr">23</xref>). Phenotypic approaches employ computational tools to analyze clinical, biomarker, and genetic data, aiming to discover more homogeneous subpopulations within sepsis patients (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>). This technology facilitates precise therapy delivery, guaranteeing that the appropriate patient receives the exact treatment at the designated time. In other fields, such as oncology, phenotypic methodologies have enhanced therapeutic accuracy (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>). Leveraging these advancements, sepsis treatment could be revolutionized, perhaps leading to the identification of new biomarkers and therapeutic targets that correspond to phenotypic differences in treatment response, thus enhancing patient outcomes.</p><p>This review examines current advancements in sepsis phenotyping (<xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1</bold>
</xref>), highlighting the potential of these methods to tackle sepsis heterogeneity and optimize treatment protocols. We aim to establish a foundation for the identification of novel biomarkers and targeted treatments based on differential responses among sepsis subtypes, ultimately enhancing patient outcomes.</p><fig position="float" id="f1"><label>Figure&#x000a0;1</label><caption><p>Chronology of the developmental history of sepsis classification. The evolution of sepsis phenotypic research from static categorization to dynamic classification has led to increasingly customized and precise treatment approaches for sepsis. Precise phenotypic classification and phenotype-based therapy strategies enhance understanding of sepsis heterogeneity, identify novel therapeutic targets, and optimize clinical treatment protocols, ultimately improving patient outcomes. Future research will focus on improving treatment outcomes through real-time monitoring and dynamic modifications to treatment protocols, aimed at addressing existing challenges in precision therapy.</p></caption><graphic xlink:href="fimmu-16-1546474-g001" position="float"/></fig></sec><sec id="s2"><label>2</label><title>The necessity of sepsis classification</title><p>Sepsis is a complex clinical disease defined by a variety of immunological responses, infection locations, and patient characteristics (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B27" ref-type="bibr">27</xref>). It is now regarded as a coexisting, dynamic proinflammatory and immunosuppressive route driven by pathogen virulence, host immunological regulation, and pharmaceutical interventions (<xref rid="B27" ref-type="bibr">27</xref>&#x02013;<xref rid="B30" ref-type="bibr">30</xref>). Sepsis-induced immunological dysregulation, which includes genetic and metabolic changes to immune cells, causes organ failure and increases the chance of re-infection after pathogen clearance (<xref rid="B31" ref-type="bibr">31</xref>&#x02013;<xref rid="B36" ref-type="bibr">36</xref>). Patient demographics, comorbidities, infection characteristics, and treatment timing all contribute to sepsis heterogeneity, which has an impact on clinical symptoms and treatment outcomes (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2</bold>
</xref>). Despite advances in sepsis research, a lack of specialized therapy options limits further success (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>).</p><fig position="float" id="f2"><label>Figure&#x000a0;2</label><caption><p>Sepsis is defined as a dysregulated host response to infection that leads to organ dysfunction. Innate immunity is inherently structured to swiftly respond to conserved molecules known as PAMPs and DAMPs, which are produced by infections and hosts, respectively. The complexities of pathogen-host interactions increase the variability of sepsis manifestations. The observed heterogeneity primarily results from pre-existing individual health conditions, variability in pathogenic bacteria, differences in infection sites, and variations in host immune responses. This variety underpins differences in clinical presentation, prognosis, and treatment outcomes, highlighting the importance of understanding sepsis diversity. Improving phenotype-based therapy techniques, identifying novel markers and targets through diverse therapeutic responses, and stratifying patients can all improve results and steer newer drugs. Pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs).</p></caption><graphic xlink:href="fimmu-16-1546474-g002" position="float"/></fig><sec id="s2_1"><label>2.1</label><title>Failures of randomized clinical trials in sepsis</title><p>In recent decades, extensive clinical trials designed to enhance sepsis treatment have predominantly failed to demonstrate significant clinical efficacy (<xref rid="B38" ref-type="bibr">38</xref>&#x02013;<xref rid="B46" ref-type="bibr">46</xref>). The trials examined several medications, including hormone therapy, immunomodulators, antibiotics, and fluid resuscitation methods. Despite these efforts, various medications, such as recombinant activated protein C, have not reliably decreased mortality or enhanced organ function, with some associated with adverse side effects (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B46" ref-type="bibr">46</xref>). Likewise, the reliance on therapies targeting individual pathways, such as anti-inflammatory cytokines like IL-1 and IL-6, fails to address the complex interplay of pro-inflammatory and anti-inflammatory responses in sepsis (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>). The primary reason for these failures lies in the assumption that sepsis is a homogenous condition, treatable with a &#x0201c;one-size-fits-all&#x0201d; approach. Research on antibiotics and fluid resuscitation has underscored the intricacies of sepsis management, revealing a lack of consensus regarding optimal treatment protocols (<xref rid="B43" ref-type="bibr">43</xref>&#x02013;<xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B47" ref-type="bibr">47</xref>&#x02013;<xref rid="B49" ref-type="bibr">49</xref>). Many RCTs lack robust stratification of patients by phenotype, leading to diluted efficacy signals and conflicting results. An example of this heterogeneity can be seen in patients with macrophage activation syndrome (MAS), a hyperinflammatory condition associated with sepsis. Studies have shown that these patients may benefit from IL-1 receptor antagonists, highlighting the importance of targeted therapies for specific subgroups (<xref rid="B41" ref-type="bibr">41</xref>). These insights underscore the need to move beyond conventional RCT designs and develop phenotype-driven approaches that tailor interventions to patient-specific profiles.</p><p>The failures of these trials highlight the importance of understanding sepsis heterogeneity at the molecular and clinical levels. Stratifying patients by genetic, molecular, and clinical phenotypes could enhance the precision of trials and allow the identification of subgroup-specific responses. And adaptive designs that allow modifications based on interim data can better accommodate the dynamic nature of sepsis and its heterogeneous population. Meanwhile, addressing the interplay of multiple pathways using combination therapies or network-driven strategies may prove more effective than single-target interventions. By addressing these issues, future trials can better align with the complexity of sepsis and pave the way for more effective treatments.</p></sec><sec id="s2_2"><label>2.2</label><title>Deciphering sepsis heterogeneity: implications for phenotype-based therapies</title><p>Progress in genomic and transcriptomic technologies has revealed that sepsis has several subphenotypes, each associated with distinct clinical consequences. These findings highlight the promise of phenotype-driven therapies to surpass the limitations of traditional sepsis treatments. Initial research utilizing genetic analysis identified numerous sepsis subphenotypes exhibiting diverse clinical outcomes. An investigation of whole genome expression in whole blood RNA from 98 adolescent septic shock patients in 2009 uncovered numerous novel findings (<xref rid="B24" ref-type="bibr">24</xref>). This is the inaugural phenotypic investigation of septic shock patients, revealing three subphenotypes characterized by distinct immune response patterns and varying degrees of illness severity (<xref rid="B24" ref-type="bibr">24</xref>). Subsequent research corroborated these findings, indicating that gene expression profiling can delineate sepsis subgroups with varying treatment responses (<xref rid="B50" ref-type="bibr">50</xref>&#x02013;<xref rid="B52" ref-type="bibr">52</xref>). In a 2015 study, researchers employed NanoString nCounter to quantify messenger RNA (mRNA) for 100 categorized genes, demonstrating gene expression mosaicism. Notwithstanding the enhancement, the model only identified subphenotypes A and B in the two cohorts (n=168 and n=132) (<xref rid="B52" ref-type="bibr">52</xref>). Subtype A activates glucocorticoid receptors to a lesser extent than subtype B (<xref rid="B52" ref-type="bibr">52</xref>). This prompted researchers to investigate adjuvant corticosteroid therapy and its prognostic implications. Adjuvant corticosteroids were administered to 52 (43%) of 120 patients with subphenotype A and 104 (58%) of 180 patients with subtype B. Corticosteroid therapy markedly decreased mortality in subtype A, but not in subtype B (<xref rid="B52" ref-type="bibr">52</xref>). This research is the first investigation of phenotype-directed therapy in septic shock patients by gene expression profiling to ascertain therapeutic heterogeneity in sepsis. Nonetheless, the administration of corticosteroids is non-randomized.</p><p>Furthermore, recent studies have shown demonstrated diversity in sepsis recovery (<xref rid="B53" ref-type="bibr">53</xref>&#x02013;<xref rid="B55" ref-type="bibr">55</xref>). Research indicates that long-term outcomes differ, with numerous survivors facing persistent physical and psychological challenges (<xref rid="B56" ref-type="bibr">56</xref>&#x02013;<xref rid="B62" ref-type="bibr">62</xref>). A 2021 study identified three distinct paths of depressive symptoms in septic shock survivors, highlighting the importance of personalized post- intensive care unit (ICU) care (<xref rid="B59" ref-type="bibr">59</xref>). Another study of clinical and biomarker data from 467 septic shock survivors identified two subgroups post-ICU discharge: Type A, characterized by low multi-organ dysfunction, and Type B, with a higher one-year mortality rate (34% vs. 16%) (<xref rid="B55" ref-type="bibr">55</xref>). Enhancing patient outcomes necessitates comprehending sepsis heterogeneity and developing phenotype-based therapeutics. The integration of epigenomics, transcriptomics, proteomics, metabolomics and cytomics with AI technologies is essential for advancing precision therapies in sepsis. This integration aids in identifying biomarkers and molecular signatures associated with sepsis subphenotypes, enhancing patient classification and treatment development. By integrating genetic and clinical data, researchers might enhance their comprehension of sepsis heterogeneity and develop stratified trial designs that consider subphenotype responses. This methodology establishes a robust framework for the identification of novel biomarkers and therapeutic targets, facilitating personalized treatments that enhance clinical outcomes and optimize therapeutic interventions.</p></sec></sec><sec id="s3"><label>3</label><title>Bridging sepsis subphenotypes to treatment strategies</title><p>Sepsis exhibits significant variability and presents management challenges; thus, defining its subphenotypes is essential for improving treatment. Recently emerging multi-omics technologies, including epigenomics, transcriptomics, proteomics, metabolomics, and cytomics, have enabled the molecular classification of sepsis (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3</bold>
</xref>). When integrated with vital signs, biochemical markers, and evaluations of organ function, these technologies elucidate the pathophysiological underpinnings of sepsis. Epigenomic changes, such as DNA methylation and histone irregularities, influence immunological responses and disease outcomes. Transcriptomic and proteomic analyses reveal gene expression patterns and protein biomarkers associated with clinical variability in sepsis patients, facilitating the identification of biomarkers and therapeutic targets. Moreover, artificial intelligence (AI) and machine learning (ML) are extensively employed to analyze these high-dimensional datasets to identify novel disease patterns and predict patient outcomes (<xref rid="T1" ref-type="table">
<bold>Table&#x000a0;1</bold>
</xref>). K-means clustering and latent profile analysis have been employed to identify clinically significant subgroups, categorizing patients according to clinical and genomic data to facilitate more personalized therapeutic decisions (<xref rid="B63" ref-type="bibr">63</xref>&#x02013;<xref rid="B65" ref-type="bibr">65</xref>). Supervised learning methods such as random forests and logistic regression can identify the onset of sepsis and enhance fluid resuscitation and antibiotic treatment (<xref rid="B64" ref-type="bibr">64</xref>, <xref rid="B66" ref-type="bibr">66</xref>&#x02013;<xref rid="B70" ref-type="bibr">70</xref>). AI/ML methodologies integrated with clinical data can design individualized therapy regimens that enhance clinical outcomes (<xref rid="B71" ref-type="bibr">71</xref>&#x02013;<xref rid="B77" ref-type="bibr">77</xref>). Artificial Intelligence and Machine Learning exhibit potential (<xref rid="B78" ref-type="bibr">78</xref>, <xref rid="B79" ref-type="bibr">79</xref>); yet, their incorporation into clinical practice necessitates thorough validation and external verification to ensure their dependability and relevance across diverse healthcare environments.</p><fig position="float" id="f3"><label>Figure&#x000a0;3</label><caption><p>Advancements in big data and artificial intelligence (AI) have enhanced the integration of clinical, biomarker, and molecular data, facilitating a deeper understanding of sepsis heterogeneity. Although classifications of sepsis subtypes differ due to variations in study designs and methodologies, these technologies facilitate the identification of novel biomarkers and therapeutic targets. The integration of multi-omics data with artificial intelligence is essential for advancing precision medicine, refining patient stratification, and directing phenotype-based therapy. By integrating genetic and clinical data, researchers can enhance the comprehension of sepsis heterogeneity and formulate stratified trials, facilitating the development of personalized medications that optimize patient outcomes.</p></caption><graphic xlink:href="fimmu-16-1546474-g003" position="float"/></fig><table-wrap position="float" id="T1"><label>Table&#x000a0;1</label><caption><p>Overview of the methods of machine learning and artificial intelligence.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Category</th><th valign="middle" align="center" rowspan="1" colspan="1">Method</th><th valign="middle" align="center" rowspan="1" colspan="1">Primary Application</th><th valign="middle" align="center" rowspan="1" colspan="1">Key Features</th><th valign="middle" align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td valign="middle" rowspan="3" align="center" colspan="1">Unsupervised</td><td valign="middle" align="left" style="" rowspan="1" colspan="1">K-means Clustering</td><td valign="middle" align="left" rowspan="1" colspan="1">Identifying subphenotypes</td><td valign="middle" align="left" style="" rowspan="1" colspan="1">Simple, interpretable; sensitive to outliers</td><td valign="middle" align="center" rowspan="1" colspan="1">Huang et&#x000a0;al. (<xref rid="B64" ref-type="bibr">64</xref>)</td></tr><tr><td valign="middle" align="left" style="" rowspan="1" colspan="1">Latent Profile Analysis</td><td valign="middle" align="left" rowspan="1" colspan="1">Revealing subphenotypes</td><td valign="middle" align="left" style="" rowspan="1" colspan="1">Captures heterogeneity; requires large datasets</td><td valign="middle" align="center" rowspan="1" colspan="1">Liu et&#x000a0;al. (<xref rid="B65" ref-type="bibr">65</xref>)</td></tr><tr><td valign="middle" align="left" style="" rowspan="1" colspan="1">Self-Organizing Maps</td><td valign="middle" align="left" rowspan="1" colspan="1">Clustering high-dimensional data</td><td valign="middle" align="left" style="" rowspan="1" colspan="1">Effective visualization; computationally intensive</td><td valign="middle" align="center" rowspan="1" colspan="1">De Zuani et&#x000a0;al. (<xref rid="B74" ref-type="bibr">74</xref>)</td></tr><tr><td valign="middle" rowspan="10" align="center" colspan="1">Supervised</td><td valign="middle" align="left" style="" rowspan="1" colspan="1">Logistic Regression</td><td valign="middle" align="left" rowspan="1" colspan="1">Predicting onset, severity</td><td valign="middle" align="left" style="" rowspan="1" colspan="1">Simple for binary outcomes; limited to linear relationships</td><td valign="middle" align="center" rowspan="1" colspan="1">Sun et&#x000a0;al. (<xref rid="B67" ref-type="bibr">67</xref>)</td></tr><tr><td valign="middle" align="left" style="" rowspan="1" colspan="1">Random Forest</td><td valign="middle" align="left" rowspan="1" colspan="1">Predicting outcomes</td><td valign="middle" align="left" style="" rowspan="1" colspan="1">Robust, non-linear; computationally expensive</td><td valign="middle" align="center" rowspan="1" colspan="1">Kijpaisalratana et&#x000a0;al. (<xref rid="B73" ref-type="bibr">73</xref>)</td></tr><tr><td valign="middle" align="left" style="" rowspan="1" colspan="1">Decision Tree</td><td valign="middle" align="left" rowspan="1" colspan="1">Treatment guidance</td><td valign="middle" align="left" style="" rowspan="1" colspan="1">Easy to interpret; prone to overfitting</td><td valign="middle" align="center" rowspan="1" colspan="1">Wang et&#x000a0;al. (<xref rid="B72" ref-type="bibr">72</xref>)</td></tr><tr><td valign="middle" align="left" style="" rowspan="1" colspan="1">Support Vector Machines</td><td valign="middle" align="left" rowspan="1" colspan="1">Classifying subphenotypes</td><td valign="middle" align="left" style="" rowspan="1" colspan="1">Effective for high-dimensional data; sensitive to parameter tuning</td><td valign="middle" align="center" rowspan="1" colspan="1">Turki et&#x000a0;al. (<xref rid="B76" ref-type="bibr">76</xref>)</td></tr><tr><td valign="middle" align="left" style="" rowspan="1" colspan="1">Gradient Boosting/XGBoost</td><td valign="middle" align="left" rowspan="1" colspan="1">Predicting outcomes</td><td valign="middle" align="left" style="" rowspan="1" colspan="1">High accuracy; computationally intensive</td><td valign="middle" align="center" rowspan="1" colspan="1">Berg et&#x000a0;al. (<xref rid="B70" ref-type="bibr">70</xref>)</td></tr><tr><td valign="middle" align="left" style="" rowspan="1" colspan="1">Deep Learning</td><td valign="middle" align="left" rowspan="1" colspan="1">Time-series prediction</td><td valign="middle" align="left" style="" rowspan="1" colspan="1">Effective for sequential data; requires large datasets</td><td valign="middle" align="center" rowspan="1" colspan="1">Lauritsen et&#x000a0;al. (<xref rid="B75" ref-type="bibr">75</xref>)</td></tr><tr><td valign="middle" align="left" style="" rowspan="1" colspan="1">Artificial Neural Networks</td><td valign="middle" align="left" rowspan="1" colspan="1">Personalized treatment prediction</td><td valign="middle" align="left" style="" rowspan="1" colspan="1">Processes high-dimensional data; requires large datasets</td><td valign="middle" align="center" rowspan="1" colspan="1">Loftus et&#x000a0;al. (<xref rid="B77" ref-type="bibr">77</xref>)</td></tr><tr><td valign="middle" align="left" style="" rowspan="1" colspan="1">K-Nearest Neighbors</td><td valign="middle" align="left" rowspan="1" colspan="1">Predicting incidence</td><td valign="middle" align="left" style="" rowspan="1" colspan="1">Intuitive; sensitive to irrelevant features</td><td valign="middle" align="center" rowspan="1" colspan="1">Michelson et&#x000a0;al. (<xref rid="B68" ref-type="bibr">68</xref>)</td></tr><tr><td valign="middle" align="left" style="" rowspan="1" colspan="1">Ensemble Methods</td><td valign="middle" align="left" rowspan="1" colspan="1">Improving classification accuracy</td><td valign="middle" align="left" style="" rowspan="1" colspan="1">Reduces overfitting; difficult to interpret</td><td valign="middle" align="center" rowspan="1" colspan="1">Wang et&#x000a0;al. (<xref rid="B72" ref-type="bibr">72</xref>)</td></tr><tr><td valign="middle" align="left" style="" rowspan="1" colspan="1">Transfer Learning</td><td valign="middle" align="left" rowspan="1" colspan="1">Adapting models for data-scarce settings</td><td valign="middle" align="left" style="" rowspan="1" colspan="1">Effective with pre-trained models; transfer not always perfect</td><td valign="middle" align="center" rowspan="1" colspan="1">Dieckhaus et&#x000a0;al. (<xref rid="B69" ref-type="bibr">69</xref>)</td></tr><tr><td valign="middle" rowspan="3" align="center" colspan="1">Specialized</td><td valign="middle" align="left" style="" rowspan="1" colspan="1">Latent Class Analysis</td><td valign="middle" align="left" rowspan="1" colspan="1">Classifying latent subgroups</td><td valign="middle" align="left" style="" rowspan="1" colspan="1">Identifies hidden groups; sensitive to class assumptions</td><td valign="middle" align="center" rowspan="1" colspan="1">Cai et&#x000a0;al. (<xref rid="B63" ref-type="bibr">63</xref>)</td></tr><tr><td valign="middle" align="left" style="" rowspan="1" colspan="1">Dynamic Treatment Regime</td><td valign="middle" align="left" rowspan="1" colspan="1">Personalized treatment strategies</td><td valign="middle" align="left" style="" rowspan="1" colspan="1">Dynamic recommendations; complex computation</td><td valign="middle" align="center" rowspan="1" colspan="1">Ma et&#x000a0;al. (<xref rid="B152" ref-type="bibr">152</xref>)</td></tr><tr><td valign="middle" align="left" style="" rowspan="1" colspan="1">Dynamic Time Warping</td><td valign="middle" align="left" rowspan="1" colspan="1">Aligning and comparing time-series data</td><td valign="middle" align="left" style="" rowspan="1" colspan="1">Effective for sequence comparison; computationally expensive</td><td valign="middle" align="center" rowspan="1" colspan="1">Bhavani et&#x000a0;al. (<xref rid="B71" ref-type="bibr">71</xref>)</td></tr></tbody></table></table-wrap><sec id="s3_1"><label>3.1</label><title>Multi-omics-based studies</title><p>Sepsis is complex, thus knowing its molecular basis is crucial. Integrating Epigenomics, transcriptomics, proteomics, metabolomics, and cytomics data offers a comprehensive view of sepsis phenotyping (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3</bold>
</xref>). These methodologies delineate molecular subphenotypes, categorize patients, and formulate personalized treatment strategies. The following discussion addresses each omics technology and their potential synergy in the understanding and management of sepsis.</p><sec id="s3_1_1"><label>3.1.1</label><title>Epigenomics</title><p>Epigenomics examines heritable modifications in gene expression that do not include alterations to the DNA sequence, including DNA methylation, histone modifications, and non-coding RNA. These epigenetic modifications significantly influence the immune response to sepsis. One study identified unique DNA methylation patterns in sepsis patients, correlating hypermethylation of immune regulatory genes with impaired immunological function (<xref rid="B80" ref-type="bibr">80</xref>). Another investigation identified histone modifications associated with sepsis-induced immune tolerance, offering insights into potentially reversible mechanisms (<xref rid="B81" ref-type="bibr">81</xref>). These findings underscore the epigenome&#x02019;s pivotal role in defining molecular subtypes of sepsis and its potential therapeutic implications. Nonetheless, despite its promise, epigenomics possesses constraints. Epigenetic modifications can be affected by numerous environmental and temporal factors, complicating the establishment of definitive causality in sepsis. Moreover, the transient nature of many epigenetic modifications, coupled with the intricate relationships within the epigenome, complicates the ability to reach definitive findings. Epigenomics provides essential insights into the regulatory mechanisms of sepsis, sometimes complemented by transcriptomics, which captures real-time gene expression alterations and reveals more dynamic molecular endophenotypes of the condition.</p></sec><sec id="s3_1_2"><label>3.1.2</label><title>Transcriptomics</title><p>Transcriptomics focuses on gene expression profiling to classify molecular endophenotypes of sepsis, which reveal significant variations in treatment responses and outcomes. Cohort studies employing unsupervised clustering to assess blood leukocyte gene expression data typically discern molecular subphenotypes of sepsis (<xref rid="B82" ref-type="bibr">82</xref>, <xref rid="B83" ref-type="bibr">83</xref>). Comprehending the diverse forms of sepsis and tailoring treatment to specific phenotypes can enhance patient outcomes. Multi-omics approaches, particularly transcriptomics, have provided significant insights into the immunological dysregulation and genetic markers that characterize sepsis subphenotypes (<xref rid="B82" ref-type="bibr">82</xref>&#x02013;<xref rid="B84" ref-type="bibr">84</xref>).</p><p>Transcriptomics-based studies have identified several molecular subphenotypes associated with distinct immune responses in sepsis patients. For example, a transcriptomic analysis of peripheral white blood cells from 265 adult sepsis patients in the ICU with community-acquired pneumonia was published in 2016. This investigation identified two significant transcriptome signatures&#x02014;SRS 1 and SRS 2&#x02014;that are associated with a bad and favorable prognosis, respectively (<xref rid="B82" ref-type="bibr">82</xref>). These signatures were confirmed across numerous cohorts and contributed to the development of gene classifiers capable of accurately predicting sepsis subphenotypes (<xref rid="B82" ref-type="bibr">82</xref>, <xref rid="B85" ref-type="bibr">85</xref>, <xref rid="B86" ref-type="bibr">86</xref>). Importantly, SRS 1 was associated with immunosuppression, whereas SRS 2 was associated with a more active immune response (<xref rid="B82" ref-type="bibr">82</xref>). Moreover, dynamic changes in SRS subgroup membership were observed during ICU stays (<xref rid="B85" ref-type="bibr">85</xref>).</p><p>A significant issue in transcriptomics research has been the absence of standardized protocols, leading to variability among studies. Recent initiatives to enhance research methodologies and replicate results across cohorts have yielded more dependable and reproducible outputs. For example, a gene expression analysis utilizing whole blood mRNA microarray data from diverse infection sources, including pneumonia and peritonitis, identified similarities and differences in immune responses, contributing to the characterization of sepsis subphenotypes (Mars1-4) (<xref rid="B83" ref-type="bibr">83</xref>). The Mars1 endophenotype, characterized by diminished gene expression in innate and adaptive immune functions such as toll-like receptor and T-cell receptor signaling pathways, was linked to unfavorable prognosis (<xref rid="B83" ref-type="bibr">83</xref>). Endophenotype indicators, specifically <italic>BPGM</italic> and <italic>TAP 2</italic>, were identified to enhance clinical application, predicting Mars1 (<xref rid="B83" ref-type="bibr">83</xref>). TAP 2 and TAP 1 constitute the TAP complex, responsible for transporting exogenous protein fragments (peptides) to the endoplasmic reticulum. The peptide is presented on the cell surface by major histocompatibility complex (MHC) class I proteins and identified by CD8+ T lymphocytes. If the peptide is detrimental, the immune system combats the intruders (<xref rid="B87" ref-type="bibr">87</xref>). These findings underscore the significance of personalized treatment strategies informed by molecular markers, rather than broad-spectrum medicines.</p><p>Research indicates that sepsis subphenotypes influence the effectiveness of immunomodulatory therapies (<xref rid="T2" ref-type="table">
<bold>Table&#x000a0;2</bold>
</xref>). A retrospective examination of gene expression in 176 septic shock patients from the VANISH clinical study, utilizing mRNA data, identified two SRS subphenotypes (SRS 1 and SRS 2) and assessed their impact on reactions to vasoactive drugs and steroids (<xref rid="B86" ref-type="bibr">86</xref>). The VANISH clinical trials randomly allocated patients to receive either norepinephrine or vasopressin within six hours of shock onset, thereafter administering hydrocortisone or a placebo (<xref rid="B43" ref-type="bibr">43</xref>). Patients displaying the immunosuppressive SRS 1 signature had a neutral response to steroid therapy, while those with the immune-active SRS 2 signature encountered worsened results (<xref rid="B86" ref-type="bibr">86</xref>). The restricted sample size may have negatively impacted the SRS 2 subgroup, resulting in an increased mortality rate. Numerous studies have investigated transcriptome-derived phenotypes, particularly with corticosteroid therapy. In 2020, researchers analyzed and incorporated 12 GEO and ArrayExpress datasets containing whole blood gene expression data from 1,613 adult sepsis patients (<xref rid="B88" ref-type="bibr">88</xref>). This research identified two sepsis subtypes (Class 1 and Class 2) by the application of deep learning methodologies and autoencoders for feature extraction. Class 1, characterized by immunosuppression, exhibited a significantly higher death rate compared to Class 2 (<xref rid="B88" ref-type="bibr">88</xref>). The research additionally examined the influence of sepsis subtypes on hydrocortisone response by a secondary analysis of an independent VANISH trial dataset (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B88" ref-type="bibr">88</xref>). The use of hydrocortisone elevated mortality rates in Class 2 patients, but not in Class 1 patients (<xref rid="B88" ref-type="bibr">88</xref>). This discovery underscores the necessity for comprehensive investigations into sepsis subphenotypes to enhance clinical treatment options and deepen our understanding of the complexity and treatment responsiveness of sepsis.</p><table-wrap position="float" id="T2"><label>Table&#x000a0;2</label><caption><p>Principal papers referenced in the text concerning the potential for phenotype-guided therapy in sepsis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center" rowspan="1" colspan="1">Number of<break/>Phenotypes</th><th valign="top" align="center" rowspan="1" colspan="1">Names of<break/>Sepsis Phenotypes</th><th valign="top" align="center" rowspan="1" colspan="1">Therapeutic approaches</th><th valign="top" align="center" rowspan="1" colspan="1">Research type</th><th valign="top" align="center" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">Subclass (A and B)</td><td valign="top" align="center" rowspan="1" colspan="1">Corticosteroids</td><td valign="top" align="center" rowspan="1" colspan="1">Original research</td><td valign="top" align="center" rowspan="1" colspan="1">Wong et&#x000a0;al. (<xref rid="B52" ref-type="bibr">52</xref>)</td></tr><tr><td valign="top" align="center" style="" rowspan="1" colspan="1">2</td><td valign="top" align="center" style="" rowspan="1" colspan="1">SRS (1&#x02013;2)</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Corticosteroids</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Secondary analysis</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Antcliffe et&#x000a0;al. (<xref rid="B86" ref-type="bibr">86</xref>)</td></tr><tr><td valign="top" align="center" style="" rowspan="1" colspan="1">2</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Class (1-2)</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Hydrocortisone</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Secondary analysis</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Zhang et&#x000a0;al. (<xref rid="B88" ref-type="bibr">88</xref>)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">Higher expression of BHSD1 or GLCCI1</td><td valign="top" align="center" rowspan="1" colspan="1">Hydrocortisone vs placebo</td><td valign="top" align="center" rowspan="1" colspan="1">Secondary analysis</td><td valign="top" align="center" rowspan="1" colspan="1">Cohen et&#x000a0;al. (<xref rid="B89" ref-type="bibr">89</xref>)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">IA-P and IN-P</td><td valign="top" align="center" rowspan="1" colspan="1">Hydrocortisone</td><td valign="top" align="center" rowspan="1" colspan="1">Secondary analysis</td><td valign="top" align="center" rowspan="1" colspan="1">Yao et&#x000a0;al. (<xref rid="B92" ref-type="bibr">92</xref>)</td></tr><tr><td valign="top" align="center" style="" rowspan="1" colspan="1">4</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Group (A, B, C and D)</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Balanced crystalloids vs saline for fluid resuscitation</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Secondary analysis</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Bhavani et&#x000a0;al. (<xref rid="B115" ref-type="bibr">115</xref>)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">Phenotype (&#x003b1;, &#x003b2;, &#x003b3;, and &#x003b4;)</td><td valign="top" align="center" rowspan="1" colspan="1">Eritoran (toll-like receptor 4 antagonist)</td><td valign="top" align="center" rowspan="1" colspan="1">Secondary analysis</td><td valign="top" align="center" rowspan="1" colspan="1">Seymour et&#x000a0;al. (<xref rid="B121" ref-type="bibr">121</xref>)</td></tr><tr><td valign="top" align="center" style="" rowspan="1" colspan="1">4</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Phenotype (&#x003b1;, &#x003b2;, &#x003b3;, and &#x003b4;)</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Drotrecogin alfa (activated protein C)</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Secondary analysis</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Seymour et&#x000a0;al. (<xref rid="B121" ref-type="bibr">121</xref>)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">Phenotype (&#x003b1;, &#x003b2;, &#x003b3;, and &#x003b4;)</td><td valign="top" align="center" rowspan="1" colspan="1">EGDT as standard care vs usual care</td><td valign="top" align="center" rowspan="1" colspan="1">Secondary analysis</td><td valign="top" align="center" rowspan="1" colspan="1">Seymour et&#x000a0;al. (<xref rid="B121" ref-type="bibr">121</xref>)</td></tr><tr><td valign="top" align="center" style="" rowspan="1" colspan="1">4</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Cluster (dA, dB, dC and dD)</td><td valign="top" align="center" style="" rowspan="1" colspan="1">recombinant Human thrombomodulin treatment</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Secondary analysis</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Kudo et&#x000a0;al. (<xref rid="B133" ref-type="bibr">133</xref>)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">Hypoinflammatory and hyperinflammatory</td><td valign="top" align="center" rowspan="1" colspan="1">Drotrecogin alfa (recombinant Human Activated Protein C)</td><td valign="top" align="center" rowspan="1" colspan="1">Secondary analysis</td><td valign="top" align="center" rowspan="1" colspan="1">Sinha et&#x000a0;al. (<xref rid="B145" ref-type="bibr">145</xref>)</td></tr><tr><td valign="top" align="center" style="" rowspan="1" colspan="1">2</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Hypoinflammatory and hyperinflammatory</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Corticosteroids</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Secondary analysis</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Neyton et&#x000a0;al. (<xref rid="B149" ref-type="bibr">149</xref>)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">Profile (1-4)</td><td valign="top" align="center" rowspan="1" colspan="1">Different amounts of fluid resuscitation</td><td valign="top" align="center" rowspan="1" colspan="1">Retrospective study</td><td valign="top" align="center" rowspan="1" colspan="1">Zhang et&#x000a0;al. (<xref rid="B150" ref-type="bibr">150</xref>)</td></tr><tr><td valign="top" align="center" style="" rowspan="1" colspan="1">5</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Class (1-5)</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Tailor fluid resuscitation strategy</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Original research</td><td valign="top" align="center" style="" rowspan="1" colspan="1">Ma et&#x000a0;al. (<xref rid="B152" ref-type="bibr">152</xref>)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">MOF, RD, ND, and OP</td><td valign="top" align="center" rowspan="1" colspan="1">Fluid balances</td><td valign="top" align="center" rowspan="1" colspan="1">Retrospective study</td><td valign="top" align="center" rowspan="1" colspan="1">Shald et&#x000a0;al. (<xref rid="B151" ref-type="bibr">151</xref>)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">Cluster (1-2)</td><td valign="top" align="center" rowspan="1" colspan="1">Tailor fluid resuscitation strategy</td><td valign="top" align="center" rowspan="1" colspan="1">Original research</td><td valign="top" align="center" rowspan="1" colspan="1">Zhang et&#x000a0;al. (<xref rid="B109" ref-type="bibr">109</xref>)</td></tr></tbody></table><table-wrap-foot><fn><p>SRS, sepsis response signature; IA-P, immune-adaptive prevalent; IN-P, immune-innate prevalent; EGDT.</p></fn><fn><p>early, goal-directed therapy; MOF, multi-organ failure; RD, respiratory dysfunction; ND, neurologic dysfunction; OP, other patients.</p></fn></table-wrap-foot></table-wrap><p>A further work in 2021 analyzed the correlation between corticosteroid responsiveness in septic shock patients and adrenocortical gene expression (<xref rid="B89" ref-type="bibr">89</xref>). A thorough analysis of whole blood RNA sequencing data from 697 patients across 28 medical-surgical ICUs involved in the ADRENAL experiment revealed no correlation between adrenal cortical gene expression levels and mortality (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B89" ref-type="bibr">89</xref>). A logistic regression analysis demonstrated an atypical occurrence: those treated with hydrocortisone with elevated Glucocorticoid-induced transcript 1 (<italic>GLCCI1</italic>) gene expression levels recovered from shock more rapidly than those with increased beta-hydroxysteroid dehydrogenase 1 (<italic>BHSD1</italic>) gene expression (<xref rid="B89" ref-type="bibr">89</xref>). And a 2022 study using a classifier based on 33 gene expression patterns to classify 13 sepsis datasets into three categories (<xref rid="B90" ref-type="bibr">90</xref>&#x02013;<xref rid="B92" ref-type="bibr">92</xref>). The researchers subsequently identified a minimal collection of predictive genes from differentially expressed genes (DEGs) within each subclass to accurately classify subclasses and reclassify gene expression patterns into immune-adaptive, immune-innate, and immune-coagulant subphenotypes (<xref rid="B92" ref-type="bibr">92</xref>). Given that the coagulant malfunction phenotype may not directly influence the response to glucocorticoid therapy, the researchers re-evaluated 117 patients from the VANISH clinical trial with septic shock, categorizing them as immune-adaptive or immune-innate, and investigated the impact of these subtypes on steroid therapy (<xref rid="B92" ref-type="bibr">92</xref>). The research indicated that glucocorticoids elevated death rates in the high immune adaptability cohort, supporting previous results from smaller studies and demonstrating that transcriptomically generated phenotypes could influence treatment choices (<xref rid="B92" ref-type="bibr">92</xref>). Patients in septic shock may exhibit varying corticosteroid responses attributable to gene expression differences. There is increased research on transcriptome-derived phenotypes and immune cell characteristics in individuals with sepsis (<xref rid="B93" ref-type="bibr">93</xref>). These findings assist in prognostic predictions and the assessment of treatments such as corticosteroids and vasoactive agents, which influence patients variably based on their immunological condition.</p><p>Thus, transcriptomics research has enhanced our comprehension of sepsis heterogeneity and demonstrated the potential for phenotype-based therapeutics. Precision medicine in sepsis enables the customization of therapy based on the patient&#x02019;s molecular profile, enhancing diagnosis and outcomes. The discovery and clinical application of molecular classifiers are essential for enhancing therapeutic regimens and patient survival rates. Transcriptomics offers valuable insights into gene expression related to sepsis, although it does not directly reflect functional outcomes. Proteomics examines proteins, the functional outcomes of gene expression, to enhance comprehension of sepsis heterogeneity.</p></sec><sec id="s3_1_3"><label>3.1.3</label><title>Proteomics</title><p>The heterogeneity of patient reactions in sepsis complicates clinical care and impedes the development of effective, personalized therapeutics (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B94" ref-type="bibr">94</xref>, <xref rid="B95" ref-type="bibr">95</xref>). Proteomics provides insights into the functional protein landscape in sepsis, unveiling key biomarkers associated with disease severity and outcomes (<xref rid="B96" ref-type="bibr">96</xref>, <xref rid="B97" ref-type="bibr">97</xref>). By identifying important plasma proteins and their connections with disease severity, organ dysfunction, and patient outcomes, proteomics aids in the understanding of the mechanisms behind sepsis heterogeneity and the development of precision medicine solutions.</p><p>Recent studies have shown the effectiveness of proteomic markers in stratifying patients with sepsis. In 2022, researchers employed proteomics to differentiate between children with sepsis who developed ARDS and those who did not (<xref rid="B97" ref-type="bibr">97</xref>). The study identified significant markers, including S100A8, S100A12, and superoxide dismutase (SOD), in plasma that were higher in individuals with ARDS (<xref rid="B97" ref-type="bibr">97</xref>). S100A8/A9, a calcium-binding heterodimer predominantly located in neutrophils and monocytes, possesses pro-inflammatory and immunosuppressive characteristics and is integral to the etiology of sepsis. It is considered a potential biomarker for sepsis and its related organ damage (<xref rid="B98" ref-type="bibr">98</xref>). Therapeutic approaches targeting S100A8/A9 may help reduce tissue damage resulting from inflammation and enhance prognosis. The findings facilitated the creation of a proteomic signature that effectively distinguished between sepsis with and without ARDS, offering essential insights into the relevant immune systems and pinpointing potential therapeutic targets. Another large-scale study employed high-throughput mass spectrometry to examine plasma proteomes from over 1,600 sepsis patients, merging data with leukocyte transcriptomes to identify protein indicators and co-expression modules linked to sepsis severity (<xref rid="B96" ref-type="bibr">96</xref>). This study identified three distinct proteomic subgroups (SPC 1, SPC 2, and SPC 3) that were associated with clinical outcomes such as organ failure and death (<xref rid="B96" ref-type="bibr">96</xref>). For example, SPC 1 patients, who had the most severe sickness symptoms, had significantly higher mortality rates than the other subgroups (<xref rid="B96" ref-type="bibr">96</xref>). This classification stresses the importance of proteome profiling in identifying high-risk individuals and guiding treatment decisions based on the specifics of their sepsis phenotype.</p><p>Proteomics elucidates sepsis heterogeneity and facilitates the development of biomarkers that more accurately forecast disease progression and treatment outcomes. This establishes the foundation for individualized sepsis therapy that focuses on particular metabolic pathways. Proteomics may facilitate the identification of novel pharmacological targets, enhance patient classification, and optimize sepsis management, hence improving patient outcomes. Proteomics emphasizes functional molecules and proteins; nonetheless, it inadequately encompasses the biochemical dynamics of sepsis, which are crucial for understanding the systemic changes associated with the disease. Metabolomics bridges this gap by demonstrating the metabolic alterations associated with sepsis in a more dynamic manner.</p></sec><sec id="s3_1_4"><label>3.1.4</label><title>Metabolomics</title><p>Metabolomics examines metabolites, the end products of cellular processes, offering a snapshot of the biochemical changes during sepsis. Investigating metabolic alterations associated with sepsis phenotypes may reveal novel biomarkers for early identification, facilitate the prediction of organ failure, and enhance therapeutic strategies for specific patient subgroups, ultimately improving prognosis (<xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B100" ref-type="bibr">100</xref>). A 2015 study demonstrated the efficacy of metabolomics in the early identification of sepsis by differentiating between children requiring intensive care and those suitable for emergency room treatment (<xref rid="B99" ref-type="bibr">99</xref>). A combination of 14 metabolites and three protein mediators accurately indicated patients for ICU admission, highlighting the significance of metabolomics in shaping triage decisions and enhancing early intervention (<xref rid="B99" ref-type="bibr">99</xref>). While these findings are intriguing, they require validation in larger cohorts.</p><p>Current study has utilized metabolomics to identify organ dysfunction early in sepsis, in addition to detecting metabolic abnormalities. Lipid mediator profiling indicated that non-survivors exhibited elevated levels of inflammatory and pro-resolving mediators, correlating with severe respiratory failure and ARDS (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B100" ref-type="bibr">100</xref>&#x02013;<xref rid="B107" ref-type="bibr">107</xref>). A 2021 study identified three distinct metabolic groups in patients with early sepsis and sepsis-related ARDS, each associated with different mortality rates linked to plasma lipid levels (<xref rid="B107" ref-type="bibr">107</xref>). Patients with high lipid levels exhibited the lowest mortality rates and a diminished risk of organ dysfunction (<xref rid="B107" ref-type="bibr">107</xref>). Notwithstanding these promising outcomes, the therapeutic efficacy of the notion remains uncertain, necessitating further validation. A recent study distinguished sepsis from septic shock by analyzing plasma metabolites within 48 hours of ICU admission, uncovering distinct metabolic patterns that may facilitate early diagnosis and treatment timing (<xref rid="B108" ref-type="bibr">108</xref>). Nonetheless, additional comprehensive validation studies and improvement of metabolite combinations remain necessary for early risk prediction.</p><p>Metabolomics has the potential to transform sepsis treatment by enhancing early detection, forecasting organ failure, and distinguishing phenotypic subgroups with varying reactions to medication. Similar to transcriptomics and proteomics, metabolomic data alone cannot adequately capture the complexity of sepsis phenotypes. Metabolomics reflects the biochemical changes occurring during sepsis, it does not account for the cellular processes and immune system dysfunction that drive disease progression. Cytomics, which focuses on the phenotypic and functional diversity of immune cells, is essential for completing the biological picture of sepsis phenotyping, providing deeper insights into immune dysregulation and aiding in the development of more personalized therapeutic strategies.</p></sec><sec id="s3_1_5"><label>3.1.5</label><title>Cytomics</title><p>Cytomics investigates the phenotypic and functional heterogeneity of cells, especially immune cells, offering real-time insights on immunological dysregulation in sepsis. Advancements in single-cell RNA sequencing (scRNA-seq) and immune cell profiling have enhanced the understanding of the pathophysiology and heterogeneity of sepsis. Specific immune cell subsets and statuses, such as MS1 cells, identified as one of the four mononuclear states, have been linked to increased mortality and organ dysfunction in sepsis patients in research, serving as potential biomarkers for sepsis prediction and therapeutic intervention (<xref rid="B83" ref-type="bibr">83</xref>&#x02013;<xref rid="B85" ref-type="bibr">85</xref>). Flow cytometry and other immune profiling methodologies enhance scRNA-seq by enabling more efficient and cost-effective assessments of immune dysfunction, which may be monitored in real-time to predict patient outcomes. For example, monocyte human leukocyte antigen-DR (mHLA-DR), part of MHC-II expressed by antigen-presenting cells, is commonly measured by flow cytometry (<xref rid="B86" ref-type="bibr">86</xref>&#x02013;<xref rid="B88" ref-type="bibr">88</xref>). Studies have shown that changes in the mHLA-DR expression pattern are strongly associated with a poor outcome in individuals with septic shock (<xref rid="B89" ref-type="bibr">89</xref>&#x02013;<xref rid="B91" ref-type="bibr">91</xref>). These findings underscore the significance of mHLA-DR as a predictive biomarker and highlight the necessity of incorporating data from several immunological markers to obtain a holistic understanding of immune responses in sepsis. Ultimately, although each omics method provides valuable insights, the integration of these diverse datasets is essential for comprehending the complete complexity of sepsis and formulating effective, phenotype-driven therapeutics.</p></sec><sec id="s3_1_6"><label>3.1.6</label><title>Integrating multi-omics data for precision medicine</title><p>Sepsis heterogeneity is observable by the integration of epigenomic, transcriptomic, proteomic, metabolomic, and cytomic data. Each omics layer elucidates the molecular causes of sepsis, although their integration is the most potent. Researchers can identify stable biomarkers, molecular layer interactions, and dynamic changes by integrating this information (<xref rid="B109" ref-type="bibr">109</xref>). Transcriptomics quantifies gene expression, proteomics analyzes post-translational changes, and metabolomics examines downstream metabolic processes. These data augment our comprehension of sepsis etiology at the systemic level. Multi-omics integration revolutionizes sepsis research. High-dimensional datasets necessitate the utilization of machine learning and network-based technologies for their integration and interpretation. The integration of multi-omics enhances the classification of sepsis subphenotypes, predictions of therapy responses, and the development of the illness. Multi-omics investigations have elucidated patterns of immune dysregulation and metabolic abnormalities in sepsis, facilitating tailored therapeutic approaches (<xref rid="B109" ref-type="bibr">109</xref>, <xref rid="B110" ref-type="bibr">110</xref>). As these technologies advance, they have the potential to revolutionize sepsis management through early detection, targeted therapy, and improved long-term outcomes.</p></sec></sec><sec id="s3_2"><label>3.2</label><title>Clinical indicators-based studies</title><p>Understanding the variability in sepsis patient responses is essential for improving therapeutic outcomes, and AI and ML techniques are increasingly utilized to identify distinct sepsis subphenotypes based on clinical indicators (<xref rid="B111" ref-type="bibr">111</xref>, <xref rid="B112" ref-type="bibr">112</xref>). These approaches offer novel mechanistic pathways, therapeutic targets, and biomarkers essential for developing sepsis-specific phenotype-driven therapies. For instance, unsupervised machine learning approaches such as cluster analysis allow for the classification of sepsis patients into subphenotypes without prior assumptions, utilizing clinical data such as vital signs, white blood cell counts, and biochemical markers (<xref rid="B111" ref-type="bibr">111</xref>, <xref rid="B113" ref-type="bibr">113</xref>, <xref rid="B114" ref-type="bibr">114</xref>). A 2022 study identified and validated several novel sepsis subphenotypes based on changes in vital signs over time (<xref rid="B115" ref-type="bibr">115</xref>). This multicenter retrospective study assessed vital signs, including body temperature, heart rate, respiratory rate, and blood pressure, in 20,729 hospitalized patients with suspected infections within the initial eight hours post-admission (<xref rid="B115" ref-type="bibr">115</xref>). Four sepsis subphenotypes (Groups A, B, C, and D) exhibited variations in clinical manifestations, laboratory findings, organ impairment, and prognosis (<xref rid="B115" ref-type="bibr">115</xref>). The secondary analysis of the SMART trial compared balanced crystalloids to normal saline in critically ill patients and demonstrated that subphenotypes influenced mortality outcomes (<xref rid="B115" ref-type="bibr">115</xref>, <xref rid="B116" ref-type="bibr">116</xref>). Balanced crystalloids decreased mortality in Group D relative to normal saline (<xref rid="B115" ref-type="bibr">115</xref>). The observations indicate that sepsis subphenotypes characterized by easily obtainable vital signs may exhibit varied responses to pharmacological interventions, potentially impacting future clinical trials. Phenotype-driven therapeutic approaches customize interventions and enhance patient outcomes. Notwithstanding these advancements, the application of AI in sepsis diagnosis and treatment remains impeded by challenges such as subgroup selection and biases in training datasets (<xref rid="B117" ref-type="bibr">117</xref>&#x02013;<xref rid="B119" ref-type="bibr">119</xref>). AI and ML can enhance sepsis classification and identify individualized patient response patterns, facilitating precision therapy. These approaches can revolutionize sepsis therapy by facilitating earlier, more precise actions that improve patient outcomes when integrated with genetic data.</p><sec id="s3_2_1"><label>3.2.1</label><title>Diverse clinical phenotypes</title><p>Researchers have progressively employed various omics data (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3</bold>
</xref>) in conjunction with standard clinical and laboratory test data&#x02014;such as white blood cell counts and biochemical markers&#x02014;utilizing sophisticated big data algorithms and artificial intelligence methods to categorize sepsis phenotypes (<xref rid="B120" ref-type="bibr">120</xref>&#x02013;<xref rid="B123" ref-type="bibr">123</xref>). These projects have produced substantial insights into the diversity of sepsis and its clinical implications. A 2015 study utilizing self-organizing maps (SOMs) and K-means clustering found four clinical phenotypes among 2,533 individuals with severe sepsis or septic shock, each with unique organ failure patterns and fatality rates (<xref rid="B120" ref-type="bibr">120</xref>). A 2020 study utilizing SOM and cluster analysis on the Medicine Information Database III (MIME-III) identified four distinct sepsis subtypes, each defined by specific organ failures, underscoring the necessity for personalized treatment strategies (<xref rid="B124" ref-type="bibr">124</xref>). A notable study published in 2019 using consensus K-means clustering to assess sepsis patients (n=20,189) from 12 medical institutions and three randomized clinical trials (n=4,737) (<xref rid="B121" ref-type="bibr">121</xref>). Within six hours of admission, 29 clinical and laboratory data points from electronic health records were employed to identify four distinct phenotypes (&#x003b1;, &#x003b2;, &#x003b3;, and &#x003b4;), each defined by specific clinical characteristics and associated mortality risks (<xref rid="B121" ref-type="bibr">121</xref>). The research examined 43,086 cases, involving 31,160 unique people, to evaluate phenotypic repeatability. Simulations of three randomized controlled trials demonstrated that altering the distribution of &#x003b1; and &#x003b4; traits greatly affected trial outcomes (<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B121" ref-type="bibr">121</xref>, <xref rid="B125" ref-type="bibr">125</xref>, <xref rid="B126" ref-type="bibr">126</xref>). This study highlights the significance of accounting for phenotypic dispersion in clinical trial design, as it can affect the efficacy of treatment interventions (<xref rid="B121" ref-type="bibr">121</xref>, <xref rid="B127" ref-type="bibr">127</xref>, <xref rid="B128" ref-type="bibr">128</xref>). This study underscores the need of identifying appropriate phenotypic classifications and administering prompt therapeutic interventions, as drugs may prove ineffective or harmful if not congruent with specific patient morphologies.</p><p>Nonetheless, machine learning methodologies exhibit a deficiency in transparency, and phenotypic consistency varies across studies. Subphenotypes are typically identified using cross-sectional clinical and biochemical data, which constrains our understanding of their temporal dynamics. Recent studies have examined dynamic sepsis subtyping according to the temporal progression of the disease (<xref rid="B129" ref-type="bibr">129</xref>&#x02013;<xref rid="B131" ref-type="bibr">131</xref>). A 2022 study analyzed 642 patients across 20 hospitals, used 23 baseline clinical markers, and identified clustering through heat maps at 0, 6, 24, and 72 hours (<xref rid="B129" ref-type="bibr">129</xref>). Five organ failure symptoms (Types L1, L2, M, H1, and H2) exhibiting varied patterns and durations were validated in an independent sample of 381 individuals from 11 institutions (<xref rid="B129" ref-type="bibr">129</xref>). The two high-risk phenotypes, H1 and H2, had comparable mortality rates; however, there were significant discrepancies in baseline disease severity scores, clinical characteristics (including age and organ failure patterns), and plasma marker levels (<xref rid="B129" ref-type="bibr">129</xref>). Another study employed 72-hour sequential organ failure assessment (SOFA) score trajectories for sepsis patients, utilizing dynamic temporal warping (DTW) and hierarchical agglomerative clustering (HAC) to delineate subgroups based on trajectory data (<xref rid="B130" ref-type="bibr">130</xref>). The researchers constructed a random forest model to forecast subtype affiliation at 6 and 24 hours post-ICU admission (<xref rid="B130" ref-type="bibr">130</xref>). The study comprised 4,678 sepsis patients in the development cohort and 3,665, 12,282, and 4,804 patients in the validation cohorts. Four groups were identified: rapidly deteriorating, gradually declining, rapidly enhancing, and gradually improving. Distinct baselines, organ dysfunction, and clinical outcomes were present for each category. Although the rapidly deteriorating subtype exhibited a lower SOFA score at ICU admission (mean: 4.5) compared to the rapidly improving subtype (mortality rate: 5.5%, mean SOFA: 5.5), it nonetheless had the highest in-hospital mortality rate at 28.3% (<xref rid="B130" ref-type="bibr">130</xref>). This research identified four unique sepsis subphenotypes, each exhibiting distinct natural histories, illustrating host-pathogen interactions throughout standard treatment. Comprehending these dynamic trajectories is essential for formulating and forecasting clinical trial interventions, as it uncovers discrepancies in natural history and treatment effectiveness. Other studies employed population-based trajectory modeling to classify sepsis according to variations in body temperature, uncovering groupings with markedly distinct inflammatory profiles and fatality rates (<xref rid="B131" ref-type="bibr">131</xref>, <xref rid="B132" ref-type="bibr">132</xref>). These strategies enhance our comprehension of sepsis progression and facilitate the development of more tailored therapeutic choices.</p><p>Alongside standard clinical indicators, phenotypic assessments encompass coagulation profiles and hemodynamic evaluations. K-means clustering was employed in machine learning including 3,694 patients from three Japanese multicenter studies conducted in 2021 (<xref rid="B133" ref-type="bibr">133</xref>). The research examined the reactions of different phenotypes to recombinant human thrombomodulin (rhTM) injections and the subsequent clinical outcomes (<xref rid="B133" ref-type="bibr">133</xref>). Four distinct coagulation phenotypes were identified: dA, dB, dC, and dD. In the dA phenotypic group, rhTM therapy decreased 28-day and in-hospital mortality, although the absence of standardization or randomization (<xref rid="B133" ref-type="bibr">133</xref>). These findings highlight the therapeutic potential of phenotype-driven therapies and the importance of establishing successful therapy windows. Current research faces issues in repeatability and transparency in machine learning approaches. However, collected evidence suggests that phenotype-based interventions may have a considerable impact on sepsis therapy (<xref rid="B134" ref-type="bibr">134</xref>&#x02013;<xref rid="B137" ref-type="bibr">137</xref>). Integrating multi-omics data with dynamic clinical signs, such as alterations in inflammatory markers or hemodynamic parameters, is expected to enhance phenotypic classification. Longitudinal tracking of clinical changes enables researchers to associate genetic findings with disease progression and get a deeper understanding of sepsis features. These advancements facilitate the identification of novel biomarkers and therapeutic targets for sepsis subphenotypes, enhancing patient outcomes and customized treatment.</p></sec><sec id="s3_2_2"><label>3.2.2</label><title>Hyperinflammatory and hypoinflammatory subphenotypes</title><p>Sepsis, akin to other intricate diseases, exhibits heterogeneity, complicating treatment and diminishing the effectiveness of various research trials (<xref rid="B94" ref-type="bibr">94</xref>, <xref rid="B138" ref-type="bibr">138</xref>). Distinguishing distinct biological phenotypes that may exhibit varied responses to therapies is essential for enhancing therapeutic outcomes (<xref rid="B129" ref-type="bibr">129</xref>, <xref rid="B139" ref-type="bibr">139</xref>&#x02013;<xref rid="B144" ref-type="bibr">144</xref>). Two principal subphenotypes in sepsis&#x02014;hyperinflammatory and hypoinflammatory&#x02014;have shown significant in forecasting disease progression, treatment responses, and patient outcomes (<xref rid="B109" ref-type="bibr">109</xref>, <xref rid="B145" ref-type="bibr">145</xref>&#x02013;<xref rid="B147" ref-type="bibr">147</xref>).</p><p>These two inflammatory types were accurately identified in numerous sepsis cohorts by latent class analysis (LCA) of clinical and biomarker data (<xref rid="B145" ref-type="bibr">145</xref>). The hyperinflammatory phenotype is characterized by elevated proinflammatory cytokines, utilization of vasoactive medications, heightened risk of bacteremia, and increased death rate (<xref rid="B145" ref-type="bibr">145</xref>). The hypoinflammatory phenotype is characterized by diminished inflammatory markers, a lower risk of bacteremia, and an improved prognosis (<xref rid="B145" ref-type="bibr">145</xref>). Clinical and treatment responses differ by phenotype, suggesting that phenotype-specific strategies may enhance patient outcomes. The secondary analysis of the PROWESS SHOCK trial (N=1680) assessing recombinant human activated protein C (drotrecogin alfa) in septic shock revealed that hyperinflammatory patients exhibited superior survival rates compared to hypoinflammatory patients, who demonstrated diminished survival rates (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B145" ref-type="bibr">145</xref>). No treatment interactions were identified in the secondary analysis of the VASST trial, which compared norepinephrine to early antidiuretic hormone therapy in cases of septic shock (<xref rid="B145" ref-type="bibr">145</xref>, <xref rid="B148" ref-type="bibr">148</xref>). Nevertheless, distinctions consistent with other cohort studies emphasize the significance of phenotype in therapeutic classification.</p><p>Further investigation has examined the impact of these variables on mortality associated with sepsis-related ARDS (<xref rid="B146" ref-type="bibr">146</xref>). Hypoinflammatory patients predominantly succumbed to respiratory failure, while hyperinflammatory patients primarily perished from circulatory failure (<xref rid="B146" ref-type="bibr">146</xref>). The data indicate that addressing individual inflammatory profiles may enhance treatment customization and effectiveness. Genomic and microbiomic data suggest that hyperinflammatory individuals have elevated bacterial numbers and immunological activity, impacting metabolic and T cell response genes (<xref rid="B149" ref-type="bibr">149</xref>). Researchers employed this methodology on VANISH trial participants with transcriptome data (N=117), classifying them as hypoinflammatory or hyperinflammatory and evaluating phenotype-specific treatment benefits by logistic regression models (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B149" ref-type="bibr">149</xref>). Steroid medication influenced various phenotypes differently, with hypoinflammatory patients perhaps encountering adverse outcomes (<xref rid="B149" ref-type="bibr">149</xref>). The diverse sepsis phenotypes underscore the necessity of tailored treatment according to clinical severity and genetic factors. Phenotype-based predictive enrichment in clinical trials is advantageous as hyperinflammatory and hypoinflammatory phenotypes respond differentially to treatment.</p><p>Classifying patients based on their inflammatory profiles may aid in identifying individuals who benefit most from various medications, thereby improving the efficacy and safety of sepsis treatment. Defining and characterizing sepsis hyperinflammatory and hypoinflammatory subphenotypes clarifies clinical heterogeneity and facilitates phenotype-guided therapy. Examining biomarkers and therapeutic targets related to these traits could improve patient outcomes, inform clinical decision-making, and increase the effectiveness of sepsis treatment.</p></sec><sec id="s3_2_3"><label>3.2.3</label><title>Fluid resuscitation and recovery</title><p>Effective fluid management is essential in sepsis and septic shock to enhance hemodynamic stability and organ perfusion (<xref rid="B28" ref-type="bibr">28</xref>). A phenotype-driven strategy for fluid therapy is essential, since both excessive and inadequate fluid resuscitation can adversely affect patient outcomes. Research indicates that fluid resuscitation affects mortality risk and recovery across many sepsis subtypes (<xref rid="B150" ref-type="bibr">150</xref>, <xref rid="B151" ref-type="bibr">151</xref>). A 2018 Latent Profile Analysis of 14,993 sepsis patients showed four categories regarding fluid balance and mortality risk (<xref rid="B150" ref-type="bibr">150</xref>). The results indicated that responses to fluid resuscitation varied markedly among different morphologies. Subtype 2 got a lesser volume of fluid compared to subtype 3, which necessitated a greater volume within 24 hours. Notably, augmenting fluid administration during the initial 48 hours elevated mortality in subtype 4, while concurrently reducing mortality in subtype 3, which exhibited hallmarks of circulatory shock, including diminished mean arterial pressure and heightened vasopressor requirements (<xref rid="B150" ref-type="bibr">150</xref>). These findings underscore the necessity of tailoring fluid resuscitation to the individual characteristics of each patient.</p><p>A dynamic treatment regime (DTR) model enhanced fluid resuscitation for septic shock in 2021. More than 1,400 patients were assessed to delineate five phenotypes, ranging from the most severely ill (Phenotype 2) to the healthiest (Phenotype 5) (<xref rid="B152" ref-type="bibr">152</xref>). Early, vigorous fluid resuscitation succeeded by a de-resuscitation period to mitigate fluid excess was determined to be the optimal fluid management strategy. Phenotype-specific fluid quantities and norepinephrine dosages enhanced mortality outcomes, with certain patients gaining advantages from early administration, while others, particularly the critically ill, benefitted from delayed treatment (<xref rid="B152" ref-type="bibr">152</xref>). This study indicates that treatment for sepsis should be tailored to its varied phenotypes. A 2022 study investigated fluid balance in patients with clinical sepsis to validate these findings (<xref rid="B151" ref-type="bibr">151</xref>). Patients were classified into categories of multiple organ failure (MOF), respiratory dysfunction (RD), nervous system dysfunction (ND), and others (<xref rid="B151" ref-type="bibr">151</xref>). The data indicated considerable phenotypic differences in fluid balance and mortality. MOF exhibited the highest mortality rate at 48.4%, whilst OP demonstrated the lowest at 13.7% (<xref rid="B151" ref-type="bibr">151</xref>). At different time intervals post-therapy, MOF and ND patients exhibited the highest fluid volumes balances, indicating that fluid management must be customized for each phenotype.</p><p>A recent study proposed utilizing transcriptome data to guide fluid management in septic shock patients through a &#x02018;benefit score&#x02019; (<xref rid="B109" ref-type="bibr">109</xref>). A comprehensive review of multi-omics data from 494 septic shock patients revealed distinct subgroups with varying responses to fluid therapy strategies and established a &#x0201c;benefit score&#x0201d; derived from transcriptomic data and a proteomic signature to assist clinicians in customizing fluid management approaches (<xref rid="B109" ref-type="bibr">109</xref>). This study employs a systems biology approach utilizing multi-omics data to enhance our comprehension of sepsis heterogeneity and to offer novel strategies for personalized treatment. These findings are valuable; nevertheless, prospective validation, rapid detection methods, and cost-effectiveness analysis are necessary prior to their implementation in clinical practice.</p><p>These studies underscore the importance of accurate fluid management in sepsis treatment, along with comprehending the molecular and clinical diversity of sepsis phenotypes. Identifying and targeting phenotype-specific fluid resuscitation methods enables the optimization of treatment, diminishes complications, and ultimately enhances patient outcomes in sepsis and septic shock.</p></sec></sec></sec><sec id="s4"><label>4</label><title>Future directions for sepsis phenotyping</title><sec id="s4_1"><label>4.1</label><title>Advancing phenotype-guided therapies</title><p>Investigations into sepsis subphenotypes have yielded essential understanding of the disease&#x02019;s heterogeneity and shown the potential for phenotype-directed therapeutic strategies. The results underscore the need for additional validation and enhancement in converting subphenotypic insights into effective treatment strategies that enhance patient outcomes. A deeper comprehension of sepsis heterogeneity is essential for developing phenotype-specific treatments. Current subphenotypic research are significant, but they are limited by a lack of standardized validation across diverse demographics and clinical circumstances. Numerous studies depend on retrospective or cohort data (<xref rid="T3" ref-type="table">
<bold>Table&#x000a0;3</bold>
</xref>); nevertheless, prospective research is crucial for creating effective, real-time phenotyping instruments that can immediately impact treatment decision-making (<xref rid="B153" ref-type="bibr">153</xref>&#x02013;<xref rid="B155" ref-type="bibr">155</xref>). Clinical trials have shown that subphenotypes are associated with different treatment responses, emphasizing the necessity of screening these phenotypes ahead of time to optimize therapy and enhance prognosis. Illustrations from various domains exemplify the pragmatic efficacy of phenotype-guided therapy. In a chronic pain management study, 60 patients were randomly divided into two groups: one receiving opioid medicine guided by CYP2D6, &#x003bc;-opioid receptor (<italic>OPRM1</italic>), and catechol-O-methyltransferase (<italic>COMT</italic>) genotyping, and the other receiving standard care (<xref rid="B156" ref-type="bibr">156</xref>). The genotype-guided group experienced significantly better pain relief and quality of life compared to the control group. This case underscores the significance of integrating genetic and phenotypic data to enhance therapeutic outcomes. Similar strategies could be adapted for sepsis management, emphasizing the need for prospective studies to evaluate their applicability.</p><table-wrap position="float" id="T3"><label>Table&#x000a0;3</label><caption><p>Comparison of multi-omics and clinical indicators in sepsis phenotyping.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Category</th><th valign="middle" align="center" rowspan="1" colspan="1">Multi-omics-Based Approach</th><th valign="middle" align="center" rowspan="1" colspan="1">Clinical Indicator-Based Approach</th></tr></thead><tbody><tr><td valign="middle" align="center" style="background-color:#ecf1f9" rowspan="1" colspan="1">Core Objective</td><td valign="top" align="left" style="background-color:#ecf1f9" rowspan="1" colspan="1">&#x027a2;&#x02003;Elucidate sepsis heterogeneity; enable phenotype-driven therapies.</td><td valign="top" align="left" style="background-color:#ecf1f9" rowspan="1" colspan="1">&#x027a2;&#x02003;Rapid phenotype assessment to support clinical decisions.</td></tr><tr><td valign="middle" align="center" style="" rowspan="1" colspan="1">Advantages</td><td valign="top" align="left" style="" rowspan="1" colspan="1">&#x02022;&#x02003;Reveals biological mechanisms and therapeutic targets.<break/>&#x02022;&#x02003;Supports precise stratification and personalized treatment.<break/>&#x02022;&#x02003;Enhances reproducibility and robustness of research outcomes.</td><td valign="top" align="left" style="" rowspan="1" colspan="1">&#x02022;&#x02003;Widely accessible, simple to implement.<break/>&#x02022;&#x02003;Enables real-time monitoring and adaptive treatments.<break/>&#x02022;&#x02003;Suited for resource-constrained settings.</td></tr><tr><td valign="middle" align="center" style="background-color:#ecf1f9" rowspan="1" colspan="1">Limitations</td><td valign="top" align="left" style="background-color:#ecf1f9" rowspan="1" colspan="1">&#x02666;&#x02003;High costs and lengthy development cycles.<break/>&#x02666;&#x02003;Reliance on advanced data integration technologies.</td><td valign="top" align="left" style="background-color:#ecf1f9" rowspan="1" colspan="1">&#x02666;&#x02003;Variability in patient populations and sampling timepoints.<break/>&#x02666;&#x02003;Limited generalizability of findings to diverse cohorts.</td></tr><tr><td valign="middle" align="center" style="" rowspan="1" colspan="1">Key Insights</td><td valign="top" align="left" style="" rowspan="1" colspan="1">&#x025aa;&#x02003;Phenotype-driven identification of novel biomarkers and therapeutic targets.<break/>&#x025aa;&#x02003;Integration of machine learning for dynamic classification.</td><td valign="top" align="left" style="" rowspan="1" colspan="1">&#x025aa;&#x02003;Improved data standardization and real-time monitoring platforms..<break/>&#x025aa;&#x02003;Optimized clinical workflows for phenotype-based strategies.</td></tr><tr><td valign="middle" align="center" style="background-color:#ecf1f9" rowspan="1" colspan="1">Future Directions</td><td valign="top" align="left" style="background-color:#ecf1f9" rowspan="1" colspan="1">&#x027a2;&#x02003;Refine individualized therapies based on phenotypic diversity.<break/>&#x027a2;&#x02003;Establish multicenter collaborations for data sharing and validation.</td><td valign="top" align="left" style="background-color:#ecf1f9" rowspan="1" colspan="1">&#x027a2;&#x02003;Enhance synergy with multi-omics approaches.<break/>&#x027a2;&#x02003;Develop standardized tools for clinical phenotype evaluation.</td></tr></tbody></table></table-wrap></sec><sec id="s4_2"><label>4.2</label><title>Challenges in sepsis phenotyping</title><p>Sepsis phenotyping has several challenges, including data heterogeneity, validation difficulties, and the integration of emerging techniques such as ML and AI. The variability in patient demographics, clinical environments, and sampling methods restricts the generalizability and reliability of phenotyping studies (<xref rid="B157" ref-type="bibr">157</xref>, <xref rid="B158" ref-type="bibr">158</xref>). Establishing uniform terminology such as &#x0201c;phenotype,&#x0201d; &#x0201c;subphenotype,&#x0201d; and &#x0201c;subgroup&#x0201d; is essential for enhancing clarity and collaboration. Standardized methods, precise nomenclature, and cohesive research methodologies are essential to resolve overlaps among subphenotypes and enhance classification systems for precision medicine.</p><p>A notable challenge is the limited accessibility of contemporary multi-omics technologies, attributed to elevated costs and technical intricacies, especially in resource-limited settings (<xref rid="B1" ref-type="bibr">1</xref>). Phenotypic models should be tested across diverse populations to guarantee their global applicability and fairness in sepsis research. Interdisciplinary collaboration integrating clinical, biological, and computational expertise is crucial for synthesizing diverse datasets and improving phenotype-guided methodologies. International efforts to standardize procedures and disseminate data can accelerate discoveries and facilitate access to advanced methodologies.</p><p>Emerging tools, including machine learning and artificial intelligence, can identify underlying diversity in treatment responses, even within large studies that yield neutral results (<xref rid="B130" ref-type="bibr">130</xref>, <xref rid="B159" ref-type="bibr">159</xref>&#x02013;<xref rid="B161" ref-type="bibr">161</xref>). Despite the potential of machine learning and artificial intelligence to find variability in treatment responses and uncover novel biomarkers, obstacles such as insufficient transparency, scalability issues, and challenges in integrating into clinical workflows hinder their widespread adoption (<xref rid="B162" ref-type="bibr">162</xref>, <xref rid="B163" ref-type="bibr">163</xref>). Developing economical, interpretable AI models and scalable platforms is essential for practical implementation. Moreover, robust ethical frameworks for data protection and governance are essential for the proper utilization of patient data. Surmounting these obstacles will advance sepsis phenotyping, facilitating more tailored therapies and improved patient outcomes.</p></sec><sec id="s4_3"><label>4.3</label><title>Expanding the scope of phenotypic research</title><sec id="s4_3_1"><label>4.3.1</label><title>Cross-organ system investigations</title><p>A comprehensive understanding of sepsis requires extending beyond blood-based evaluations to incorporate cross-organ system analyses that elucidate the complex interactions influencing disease progression (<xref rid="B164" ref-type="bibr">164</xref>). Although omics technologies provide significant molecular insights, the gap between these findings and clinical results highlights the necessity for more thorough phenotypic evaluations. Sepsis often impacts many organ systems, resulting in differing levels of dysfunction; therefore, it is essential to investigate gene expression, protein function, and metabolite regulation across tissues (<xref rid="B13" ref-type="bibr">13</xref>). Broadening phenotypic studies to encompass organ-specific abnormalities, particularly in the lungs, liver, and kidneys, will enhance our comprehension of sepsis etiology and facilitate the creation of therapies aimed at organ-specific harm (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B165" ref-type="bibr">165</xref>, <xref rid="B166" ref-type="bibr">166</xref>). Future study ought to integrate multi-omics methodologies with cross-organ studies to develop a whole comprehension of sepsis and propel advancements in detection and treatment.</p></sec><sec id="s4_3_2"><label>4.3.2</label><title>The temporal dynamics of phenotypes</title><p>The evolving characteristics of sepsis phenotypes present both challenges and opportunities for precision treatment (<xref rid="B167" ref-type="bibr">167</xref>). Determining the optimal intervention window and tracking phenotypic changes is critical for tailoring therapy to individual patients and improving long-term outcomes (<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4</bold>
</xref>). Nevertheless, the majority of contemporary research employs single time-point cross-sectional data, which constrains their ability to differentiate between ephemeral chemical states and persistent phenotypic characteristics. For example, phenotypes identified in early hyperinflammatory stages may shift to immunosuppressive states during later stages of sepsis progression (<xref rid="B147" ref-type="bibr">147</xref>). Without longitudinal sampling, it is challenging to distinguish transient changes from stable molecular characteristics, potentially leading to misclassification. This limitation raises the concern that current subtyping studies may reflect transient stages of sepsis progression rather than stable, distinct patient subtypes. longitudinal sampling, coupled with multi-omics integration, can surmount these limitations by monitoring molecular and clinical markers over time. This method facilitates the discovery of stable phenotypes, improves categorization systems, and directs the development of stage-specific therapies. Emphasizing dynamic studies will allow researchers to customize treatment strategies to the evolving characteristics of sepsis, enhancing patient outcomes and advancing the field of precision medicine.</p><fig position="float" id="f4"><label>Figure&#x000a0;4</label><caption><p>Dynamic subtyping and real-time decision-making address sepsis heterogeneity by combining clinical, biomarker, and molecular data to identify more homogeneous subpopulations. This methodology promotes phenotype-driven medicines, facilitates the discovery of new markers and targets through various treatment responses, and improves patient outcomes by providing accurate pharmaceuticals to the appropriate individuals at the right time.</p></caption><graphic xlink:href="fimmu-16-1546474-g004" position="float"/></fig></sec></sec></sec><sec sec-type="conclusions" id="s5"><label>5</label><title>Conclusions</title><p>Understanding the heterogeneity of sepsis is pivotal for advancing phenotype-based therapeutic strategies and improving patient outcomes. This review synthesizes advances in clustering algorithms, multi-omics technologies, and artificial intelligence, providing a comprehensive framework for identifying distinct sepsis subtypes with varied treatment responses. These insights lay the groundwork for discovering novel biomarkers and therapeutic targets, underscoring the transformative potential of precision medicine to tailor treatments based on phenotypic diversity. However, challenges such as phenotyping standardization, dynamic data integration, and clinical translation must be addressed through interdisciplinary collaboration and innovative research. By bridging these gaps, future efforts can fully implement phenotype-driven therapies, transforming sepsis management, enhancing survival rates, and establishing a new paradigm for precision medicine in complex diseases.</p></sec></body><back><ack><title>Acknowledgments</title><p>All authors gave thanks to the West China Hospital, Sichuan University and West China Tianfu Hospital for data supply that made the study possible.</p></ack><fn-group><title>Abbreviations</title><fn fn-type="abbr" id="abbrev1"><p>AI, artificial intelligence; BHSD1, beta-hydroxysteroid dehydrogenase 1; ARDS, acute respiratory distress syndrome; COMT, catechol-O-methyltransferase; DEGs, differentially expressed genes; DTW, dynamic time warping; DTR, dynamic treatment regime; DAMPs, damage-associated molecular patterns; DIC, disseminated intravascular coagulation; GLCCI1, Glucocorticoid-induced transcript 1; HAC, hierarchical agglomerative clustering; ICUs, intensive care unit; LCA, latent class analysis; mHLA-DR, monocyte human leukocyte antigen-DR; MIME-III, Medicine Information Database III; MHC, major histocompatibility complex; mRNA, messengerRNA; MAS, macrophage activation syndrome; ML, Machine learning; OPRM1, &#x003bc;-opioid receptor; PAMPs, Pathogen-associated molecular patterns; qRT-PCR, quantitative real-time PCR; rhTM, recombinant human thrombomodulin; RCTs, randomized clinical trials; SOFA, sequential organ failure assessment; SRS, sepsis response signature; scRNA-seq, single-cell RNA sequencing; SOD, superoxide dismutase; SOMs, self-organizing maps.</p></fn></fn-group><sec sec-type="author-contributions" id="s6"><title>Author contributions</title><p>XZ: Data curation, Investigation, Validation, Visualization, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. WZ: Conceptualization, Formal analysis, Funding acquisition, Project administration, Resources, Supervision, Writing &#x02013; review &#x00026; editing. HZ: Writing &#x02013; review &#x00026; editing, Data curation, Investigation. XL: Conceptualization, Formal analysis, Funding acquisition, Project administration, Resources, Software, Supervision, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="s8"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s9"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s10"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rudd</surname><given-names>KE</given-names></name><name><surname>Johnson</surname><given-names>SC</given-names></name><name><surname>Agesa</surname><given-names>KM</given-names></name><name><surname>Shackelford</surname><given-names>KA</given-names></name><name><surname>Tsoi</surname><given-names>D</given-names></name><name><surname>Kievlan</surname><given-names>DR</given-names></name><etal/></person-group>. <article-title>Global, regional, and national sepsis incidence and mortality, 1990-2017: Analysis for the global burden of disease study</article-title>. <source>Lancet</source> (<year>2020</year>) <volume>395</volume>(<issue>10219</issue>):<page-range>200&#x02013;11</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S0140-6736(19)32989-7</pub-id>
</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sakr</surname><given-names>Y</given-names></name><name><surname>Jaschinski</surname><given-names>U</given-names></name><name><surname>Wittebole</surname><given-names>X</given-names></name><name><surname>Szakmany</surname><given-names>T</given-names></name><name><surname>Lipman</surname><given-names>J</given-names></name><name><surname>Namendys-Silva</surname><given-names>SA</given-names></name><etal/></person-group>. <article-title>Sepsis in intensive care unit patients: Worldwide data from the intensive care over nations audit</article-title>. <source>Open Forum Infect Dis</source> (<year>2018</year>) <volume>5</volume>(<issue>12</issue>):<elocation-id>ofy313</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/ofid/ofy313</pub-id>
<pub-id pub-id-type="pmid">30555852</pub-id>
</mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singer</surname><given-names>M</given-names></name><name><surname>Deutschman</surname><given-names>CS</given-names></name><name><surname>Seymour</surname><given-names>CW</given-names></name><name><surname>Shankar-Hari</surname><given-names>M</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The third international consensus definitions for sepsis and septic shock (Sepsis-3)</article-title>. <source>Jama</source> (<year>2016</year>) <volume>315</volume>(<issue>8</issue>):<page-range>801&#x02013;10</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1001/jama.2016.0287</pub-id>
</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Levy</surname><given-names>MM</given-names></name><name><surname>Artigas</surname><given-names>A</given-names></name><name><surname>Phillips</surname><given-names>GS</given-names></name><name><surname>Rhodes</surname><given-names>A</given-names></name><name><surname>Beale</surname><given-names>R</given-names></name><name><surname>Osborn</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Outcomes of the surviving sepsis campaign in intensive care units in the USA and europe: A prospective cohort study</article-title>. <source>Lancet Infect Dis</source> (<year>2012</year>) <volume>12</volume>(<issue>12</issue>):<page-range>919&#x02013;24</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S1473-3099(12)70239-6</pub-id>
</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leligdowicz</surname><given-names>A</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name></person-group>. <article-title>Heterogeneity in sepsis: New biological evidence with clinical applications</article-title>. <source>Crit Care (London England)</source> (<year>2019</year>) <volume>23</volume>(<issue>1</issue>):<fpage>80</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s13054-019-2372-2</pub-id>
</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van der Poll</surname><given-names>T</given-names></name><name><surname>Shankar-Hari</surname><given-names>M</given-names></name><name><surname>Wiersinga</surname><given-names>WJ</given-names></name></person-group>. <article-title>The immunology of sepsis</article-title>. <source>Immunity</source> (<year>2021</year>) <volume>54</volume>(<issue>11</issue>):<page-range>2450&#x02013;64</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.immuni.2021.10.012</pub-id>
</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gotts</surname><given-names>JE</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name></person-group>. <article-title>Sepsis: Pathophysiology and clinical management</article-title>. <source>BMJ (Clinical Res ed)</source> (<year>2016</year>) <volume>353</volume>:<elocation-id>i1585</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1136/bmj.i1585</pub-id>
</mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gyawali</surname><given-names>B</given-names></name><name><surname>Ramakrishna</surname><given-names>K</given-names></name><name><surname>Dhamoon</surname><given-names>AS</given-names></name></person-group>. <article-title>Sepsis: The evolution in definition, pathophysiology, and management</article-title>. <source>SAGE Open Med</source> (<year>2019</year>) <volume>7</volume>:<elocation-id>2050312119835043</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1177/2050312119835043</pub-id>
<pub-id pub-id-type="pmid">30915218</pub-id>
</mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pickkers</surname><given-names>P</given-names></name><name><surname>Kox</surname><given-names>M</given-names></name></person-group>. <article-title>Towards precision medicine for sepsis patients</article-title>. <source>Crit Care (London England)</source> (<year>2017</year>) <volume>21</volume>(<issue>1</issue>):<elocation-id>11</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s13054-016-1583-z</pub-id>
</mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prescott</surname><given-names>HC</given-names></name><name><surname>Angus</surname><given-names>DC</given-names></name></person-group>. <article-title>Enhancing recovery from sepsis: A review</article-title>. <source>Jama</source> (<year>2018</year>) <volume>319</volume>(<issue>1</issue>):<fpage>62</fpage>&#x02013;<lpage>75</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1001/jama.2017.17687</pub-id>
<pub-id pub-id-type="pmid">29297082</pub-id>
</mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Drawnel</surname><given-names>FM</given-names></name><name><surname>Zhang</surname><given-names>JD</given-names></name><name><surname>Kung</surname><given-names>E</given-names></name><name><surname>Aoyama</surname><given-names>N</given-names></name><name><surname>Benmansour</surname><given-names>F</given-names></name><name><surname>Araujo Del Rosario</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Molecular phenotyping combines molecular information, biological relevance, and patient data to improve productivity of early drug discovery</article-title>. <source>Cell Chem Biol</source> (<year>2017</year>) <volume>24</volume>(<issue>5</issue>):<fpage>624</fpage>&#x02013;<lpage>34 e3</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.chembiol.2017.03.016</pub-id>
<pub-id pub-id-type="pmid">28434878</pub-id>
</mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morelli</surname><given-names>A</given-names></name><name><surname>Passariello</surname><given-names>M</given-names></name></person-group>. <article-title>Hemodynamic coherence in sepsis</article-title>. <source>Best Pract Res Clin Anaesthesiol</source> (<year>2016</year>) <volume>30</volume>(<issue>4</issue>):<page-range>453&#x02013;63</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.bpa.2016.10.009</pub-id>
</mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lelubre</surname><given-names>C</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name></person-group>. <article-title>Mechanisms and treatment of organ failure in sepsis</article-title>. <source>Nat Rev Nephrol</source> (<year>2018</year>) <volume>14</volume>(<issue>7</issue>):<page-range>417&#x02013;27</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41581-018-0005-7</pub-id>
</mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Giustozzi</surname><given-names>M</given-names></name><name><surname>Ehrlinder</surname><given-names>H</given-names></name><name><surname>Bongiovanni</surname><given-names>D</given-names></name><name><surname>Borovac</surname><given-names>JA</given-names></name><name><surname>Guerreiro</surname><given-names>RA</given-names></name><name><surname>Gasecka</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Coagulopathy and sepsis: Pathophysiology, clinical manifestations and treatment</article-title>. <source>Blood Rev</source> (<year>2021</year>) <volume>50</volume>:<elocation-id>100864</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.blre.2021.100864</pub-id>
<pub-id pub-id-type="pmid">34217531</pub-id>
</mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Assinger</surname><given-names>A</given-names></name><name><surname>Schrottmaier</surname><given-names>WC</given-names></name><name><surname>Salzmann</surname><given-names>M</given-names></name><name><surname>Rayes</surname><given-names>J</given-names></name></person-group>. <article-title>Platelets in sepsis: An update on experimental models and clinical data</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>1687</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2019.01687</pub-id>
<pub-id pub-id-type="pmid">31379873</pub-id>
</mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fan</surname><given-names>TH</given-names></name><name><surname>Premraj</surname><given-names>L</given-names></name><name><surname>Roberts</surname><given-names>J</given-names></name><name><surname>Lydston</surname><given-names>M</given-names></name><name><surname>Robba</surname><given-names>C</given-names></name><name><surname>Hager</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>In-hospital neurologic complications, neuromonitoring, and long-term neurologic outcomes in patients with sepsis: A systematic review and meta-analysis</article-title>. <source>Crit Care Med</source> (<year>2024</year>) <volume>52</volume>(<issue>3</issue>):<page-range>452&#x02013;63</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/CCM.0000000000006096</pub-id>
</mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sekino</surname><given-names>N</given-names></name><name><surname>Selim</surname><given-names>M</given-names></name><name><surname>Shehadah</surname><given-names>A</given-names></name></person-group>. <article-title>Sepsis-associated brain injury: Underlying mechanisms and potential therapeutic strategies for acute and long-term cognitive impairments</article-title>. <source>J Neuroinflamm</source> (<year>2022</year>) <volume>19</volume>(<issue>1</issue>):<fpage>101</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12974-022-02464-4</pub-id>
</mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gattinoni</surname><given-names>L</given-names></name><name><surname>Vasques</surname><given-names>F</given-names></name><name><surname>Camporota</surname><given-names>L</given-names></name><name><surname>Meessen</surname><given-names>J</given-names></name><name><surname>Romitti</surname><given-names>F</given-names></name><name><surname>Pasticci</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Understanding lactatemia in human sepsis. potential impact for early management</article-title>. <source>Am J Respir Crit Care Med</source> (<year>2019</year>) <volume>200</volume>(<issue>5</issue>):<page-range>582&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1164/rccm.201812-2342OC</pub-id>
</mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Willmann</surname><given-names>K</given-names></name><name><surname>Moita</surname><given-names>LF</given-names></name></person-group>. <article-title>Physiologic disruption and metabolic reprogramming in infection and sepsis</article-title>. <source>Cell Metab</source> (<year>2024</year>) <volume>36</volume>(<issue>5</issue>):<page-range>927&#x02013;46</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.cmet.2024.02.013</pub-id>
</mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qiao</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name></person-group>. <article-title>Endothelial cell dynamics in sepsis-induced acute lung injury and acute respiratory distress syndrome: Pathogenesis and therapeutic implications</article-title>. <source>Cell Commun Signal</source> (<year>2024</year>) <volume>22</volume>(<issue>1</issue>):<fpage>241</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12964-024-01620-y</pub-id>
<pub-id pub-id-type="pmid">38664775</pub-id>
</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peerapornratana</surname><given-names>S</given-names></name><name><surname>Manrique-Caballero</surname><given-names>CL</given-names></name><name><surname>Gomez</surname><given-names>H</given-names></name><name><surname>Kellum</surname><given-names>JA</given-names></name></person-group>. <article-title>Acute kidney injury from sepsis: Current concepts, epidemiology, pathophysiology, prevention and treatment</article-title>. <source>Kidney Int</source> (<year>2019</year>) <volume>96</volume>(<issue>5</issue>):<page-range>1083&#x02013;99</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.kint.2019.05.026</pub-id>
</mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Strnad</surname><given-names>P</given-names></name><name><surname>Tacke</surname><given-names>F</given-names></name><name><surname>Koch</surname><given-names>A</given-names></name><name><surname>Trautwein</surname><given-names>C</given-names></name></person-group>. <article-title>Liver - guardian, modifier and target of sepsis</article-title>. <source>Nat Rev Gastroenterol Hepatol</source> (<year>2017</year>) <volume>14</volume>(<issue>1</issue>):<fpage>55</fpage>&#x02013;<lpage>66</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nrgastro.2016.168</pub-id>
<pub-id pub-id-type="pmid">27924081</pub-id>
</mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shivade</surname><given-names>C</given-names></name><name><surname>Raghavan</surname><given-names>P</given-names></name><name><surname>Fosler-Lussier</surname><given-names>E</given-names></name><name><surname>Embi</surname><given-names>PJ</given-names></name><name><surname>Elhadad</surname><given-names>N</given-names></name><name><surname>Johnson</surname><given-names>SB</given-names></name><etal/></person-group>. <article-title>A review of approaches to identifying patient phenotype cohorts using electronic health records</article-title>. <source>J Am Med Inform Assoc</source> (<year>2014</year>) <volume>21</volume>(<issue>2</issue>):<page-range>221&#x02013;30</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1136/amiajnl-2013-001935</pub-id>
</mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wong</surname><given-names>HR</given-names></name><name><surname>Cvijanovich</surname><given-names>N</given-names></name><name><surname>Lin</surname><given-names>R</given-names></name><name><surname>Allen</surname><given-names>GL</given-names></name><name><surname>Thomas</surname><given-names>NJ</given-names></name><name><surname>Willson</surname><given-names>DF</given-names></name><etal/></person-group>. <article-title>Identification of pediatric septic shock subclasses based on genome-wide expression profiling</article-title>. <source>BMC Med</source> (<year>2009</year>) <volume>7</volume>(<issue>1</issue>):<elocation-id>34</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/1741-7015-7-34</pub-id>
<pub-id pub-id-type="pmid">19624809</pub-id>
</mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aerts</surname><given-names>HJ</given-names></name><name><surname>Velazquez</surname><given-names>ER</given-names></name><name><surname>Leijenaar</surname><given-names>RT</given-names></name><name><surname>Parmar</surname><given-names>C</given-names></name><name><surname>Grossmann</surname><given-names>P</given-names></name><name><surname>Carvalho</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach</article-title>. <source>Nat Commun</source> (<year>2014</year>) <volume>5</volume>:<fpage>4006</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/ncomms5006</pub-id>
<pub-id pub-id-type="pmid">24892406</pub-id>
</mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sadanandam</surname><given-names>A</given-names></name><name><surname>Lyssiotis</surname><given-names>CA</given-names></name><name><surname>Homicsko</surname><given-names>K</given-names></name><name><surname>Collisson</surname><given-names>EA</given-names></name><name><surname>Gibb</surname><given-names>WJ</given-names></name><name><surname>Wullschleger</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>A colorectal cancer classification system that associates cellular phenotype and responses to therapy</article-title>. <source>Nat Med</source> (<year>2013</year>) <volume>19</volume>(<issue>5</issue>):<page-range>619&#x02013;25</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nm.3175</pub-id>
</mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cicchinelli</surname><given-names>S</given-names></name><name><surname>Pignataro</surname><given-names>G</given-names></name><name><surname>Gemma</surname><given-names>S</given-names></name><name><surname>Piccioni</surname><given-names>A</given-names></name><name><surname>Picozzi</surname><given-names>D</given-names></name><name><surname>Ojetti</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Pamps and damps in sepsis: A review of their molecular features and potential clinical implications</article-title>. <source>Int J Mol Sci</source> (<year>2024</year>) <volume>25</volume>(<issue>2</issue>). doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijms25020962</pub-id>
</mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cecconi</surname><given-names>M</given-names></name><name><surname>Evans</surname><given-names>L</given-names></name><name><surname>Levy</surname><given-names>M</given-names></name><name><surname>Rhodes</surname><given-names>A</given-names></name></person-group>. <article-title>Sepsis and septic shock</article-title>. <source>Lancet</source> (<year>2018</year>) <volume>392</volume>(<issue>10141</issue>):<fpage>75</fpage>&#x02013;<lpage>87</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S0140-6736(18)30696-2</pub-id>
<pub-id pub-id-type="pmid">29937192</pub-id>
</mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Angus</surname><given-names>DC</given-names></name><name><surname>van der Poll</surname><given-names>T</given-names></name></person-group>. <article-title>Severe sepsis and septic shock</article-title>. <source>N Engl J Med</source> (<year>2013</year>) <volume>369</volume>(<issue>9</issue>):<page-range>840&#x02013;51</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMra1208623</pub-id>
</mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hotchkiss</surname><given-names>RS</given-names></name><name><surname>Monneret</surname><given-names>G</given-names></name><name><surname>Payen</surname><given-names>D</given-names></name></person-group>. <article-title>Sepsis-induced immunosuppression: From cellular dysfunctions to immunotherapy</article-title>. <source>Nat Rev Immunol</source> (<year>2013</year>) <volume>13</volume>(<issue>12</issue>):<page-range>862&#x02013;74</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nri3552</pub-id>
</mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zaborin</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Garfield</surname><given-names>K</given-names></name><name><surname>Quensen</surname><given-names>J</given-names></name><name><surname>Shakhsheer</surname><given-names>B</given-names></name><name><surname>Kade</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Membership and behavior of ultra-Low-Diversity pathogen communities present in the gut of humans during prolonged critical illness</article-title>. <source>mBio</source> (<year>2014</year>) <volume>5</volume>(<issue>5</issue>):<page-range>e01361&#x02013;14</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/mBio.01361-14</pub-id>
</mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andersson</surname><given-names>U</given-names></name><name><surname>Tracey</surname><given-names>KJ</given-names></name></person-group>. <article-title>Reflex principles of immunological homeostasis</article-title>. <source>Annu Rev Immunol</source> (<year>2012</year>) <volume>30</volume>(<issue>1</issue>):<page-range>313&#x02013;35</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1146/annurev-immunol-020711-075015</pub-id>
</mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Hou</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Pkm2 regulates the warburg effect and promotes Hmgb1 release in sepsis</article-title>. <source>Nat Commun</source> (<year>2014</year>) <volume>5</volume>(<issue>1</issue>):<fpage>4436</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/ncomms5436</pub-id>
<pub-id pub-id-type="pmid">25019241</pub-id>
</mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carson</surname><given-names>WF</given-names></name><name><surname>Cavassani</surname><given-names>KA</given-names></name><name><surname>Dou</surname><given-names>Y</given-names></name><name><surname>Kunkel</surname><given-names>SL</given-names></name></person-group>. <article-title>Epigenetic regulation of immune cell functions during post-septic immunosuppression</article-title>. <source>Epigenetics</source> (<year>2011</year>) <volume>6</volume>(<issue>3</issue>):<page-range>273&#x02013;83</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4161/epi.6.3.14017</pub-id>
</mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krumholz</surname><given-names>HM</given-names></name></person-group>. <article-title>Post-hospital syndrome&#x02013;an acquired, transient condition of generalized risk</article-title>. <source>N Engl J Med</source> (<year>2013</year>) <volume>368</volume>(<issue>2</issue>):<page-range>100&#x02013;2</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMp1212324</pub-id>
</mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scales</surname><given-names>DC</given-names></name><name><surname>Fischer</surname><given-names>HD</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Bierman</surname><given-names>AS</given-names></name><name><surname>Fernandes</surname><given-names>O</given-names></name><name><surname>Mamdani</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Unintentional continuation of medications intended for acute illness after hospital discharge: A population-based cohort study</article-title>. <source>J Gen Intern Med</source> (<year>2016</year>) <volume>31</volume>(<issue>2</issue>):<fpage>196</fpage>&#x02013;<lpage>202</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s11606-015-3501-5</pub-id>
<pub-id pub-id-type="pmid">26369941</pub-id>
</mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>CF</given-names></name></person-group>. <article-title>Sepsis heterogeneity</article-title>. <source>World J Pediatr</source> (<year>2023</year>) <volume>19</volume>(<issue>10</issue>):<page-range>919&#x02013;27</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s12519-023-00689-8</pub-id>
</mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sprung</surname><given-names>CL</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Keh</surname><given-names>D</given-names></name><name><surname>Moreno</surname><given-names>R</given-names></name><name><surname>Singer</surname><given-names>M</given-names></name><name><surname>Freivogel</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Hydrocortisone therapy for patients with septic shock</article-title>. <source>N Engl J Med</source> (<year>2008</year>) <volume>358</volume>(<issue>2</issue>):<page-range>111&#x02013;24</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMoa071366</pub-id>
</mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fujii</surname><given-names>T</given-names></name><name><surname>Salanti</surname><given-names>G</given-names></name><name><surname>Belletti</surname><given-names>A</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name><name><surname>Carr</surname><given-names>A</given-names></name><name><surname>Furukawa</surname><given-names>TA</given-names></name><etal/></person-group>. <article-title>Effect of adjunctive vitamin C, glucocorticoids, and vitamin B1 on longer-term mortality in adults with sepsis or septic shock: A systematic review and a component network meta-analysis</article-title>. <source>Intensive Care Med</source> (<year>2022</year>) <volume>48</volume>(<issue>1</issue>):<fpage>16</fpage>&#x02013;<lpage>24</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00134-021-06558-0</pub-id>
<pub-id pub-id-type="pmid">34750650</pub-id>
</mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ranieri</surname><given-names>VM</given-names></name><name><surname>Thompson</surname><given-names>BT</given-names></name><name><surname>Barie</surname><given-names>PS</given-names></name><name><surname>Dhainaut</surname><given-names>JF</given-names></name><name><surname>Douglas</surname><given-names>IS</given-names></name><name><surname>Finfer</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Drotrecogin alfa (Activated) in adults with septic shock</article-title>. <source>N Engl J Med</source> (<year>2012</year>) <volume>366</volume>(<issue>22</issue>):<page-range>2055&#x02013;64</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMoa1202290</pub-id>
</mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shakoory</surname><given-names>B</given-names></name><name><surname>Carcillo</surname><given-names>JA</given-names></name><name><surname>Chatham</surname><given-names>WW</given-names></name><name><surname>Amdur</surname><given-names>RL</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><etal/></person-group>. <article-title>Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: Reanalysis of a prior phase iii trial</article-title>. <source>Crit Care Med</source> (<year>2016</year>) <volume>44</volume>(<issue>2</issue>):<page-range>275&#x02013;81</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/CCM.0000000000001402</pub-id>
</mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Investigators</surname><given-names>R-C</given-names></name><name><surname>Gordon</surname><given-names>AC</given-names></name><name><surname>Mouncey</surname><given-names>PR</given-names></name><name><surname>Al-Beidh</surname><given-names>F</given-names></name><name><surname>Rowan</surname><given-names>KM</given-names></name><name><surname>Nichol</surname><given-names>AD</given-names></name><etal/></person-group>. <article-title>Interleukin-6 receptor antagonists in critically ill patients with covid-19</article-title>. <source>N Engl J Med</source> (<year>2021</year>) <volume>384</volume>(<issue>16</issue>):<page-range>1491&#x02013;502</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMoa2100433</pub-id>
</mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gordon</surname><given-names>AC</given-names></name><name><surname>Mason</surname><given-names>AJ</given-names></name><name><surname>Thirunavukkarasu</surname><given-names>N</given-names></name><name><surname>Perkins</surname><given-names>GD</given-names></name><name><surname>Cecconi</surname><given-names>M</given-names></name><name><surname>Cepkova</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: The vanish randomized clinical trial</article-title>. <source>Jama</source> (<year>2016</year>) <volume>316</volume>(<issue>5</issue>):<page-range>509&#x02013;18</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1001/jama.2016.10485</pub-id>
</mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pro</surname><given-names>CI</given-names></name><name><surname>Yealy</surname><given-names>DM</given-names></name><name><surname>Kellum</surname><given-names>JA</given-names></name><name><surname>Huang</surname><given-names>DT</given-names></name><name><surname>Barnato</surname><given-names>AE</given-names></name><name><surname>Weissfeld</surname><given-names>LA</given-names></name><etal/></person-group>. <article-title>A randomized trial of protocol-based care for early septic shock</article-title>. <source>N Engl J Med</source> (<year>2014</year>) <volume>370</volume>(<issue>18</issue>):<page-range>1683&#x02013;93</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMoa1401602</pub-id>
</mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Young</surname><given-names>P</given-names></name><name><surname>Bailey</surname><given-names>M</given-names></name><name><surname>Beasley</surname><given-names>R</given-names></name><name><surname>Henderson</surname><given-names>S</given-names></name><name><surname>Mackle</surname><given-names>D</given-names></name><name><surname>McArthur</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: The split randomized clinical trial</article-title>. <source>Jama</source> (<year>2015</year>) <volume>314</volume>(<issue>16</issue>):<page-range>1701&#x02013;10</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1001/jama.2015.12334</pub-id>
</mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Venkatesh</surname><given-names>B</given-names></name><name><surname>Finfer</surname><given-names>S</given-names></name><name><surname>Cohen</surname><given-names>J</given-names></name><name><surname>Rajbhandari</surname><given-names>D</given-names></name><name><surname>Arabi</surname><given-names>Y</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Adjunctive glucocorticoid therapy in patients with septic shock</article-title>. <source>N Engl J Med</source> (<year>2018</year>) <volume>378</volume>(<issue>9</issue>):<fpage>797</fpage>&#x02013;<lpage>808</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMoa1705835</pub-id>
<pub-id pub-id-type="pmid">29347874</pub-id>
</mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sawyer</surname><given-names>RG</given-names></name><name><surname>Claridge</surname><given-names>JA</given-names></name><name><surname>Nathens</surname><given-names>AB</given-names></name><name><surname>Rotstein</surname><given-names>OD</given-names></name><name><surname>Duane</surname><given-names>TM</given-names></name><name><surname>Evans</surname><given-names>HL</given-names></name><etal/></person-group>. <article-title>Trial of short-course antimicrobial therapy for intraabdominal infection</article-title>. <source>N Engl J Med</source> (<year>2015</year>) <volume>372</volume>(<issue>21</issue>):<fpage>1996</fpage>&#x02013;<lpage>2005</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMoa1411162</pub-id>
<pub-id pub-id-type="pmid">25992746</pub-id>
</mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harris</surname><given-names>PNA</given-names></name><name><surname>Tambyah</surname><given-names>PA</given-names></name><name><surname>Lye</surname><given-names>DC</given-names></name><name><surname>Mo</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>TH</given-names></name><name><surname>Yilmaz</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with e coli or klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: A randomized clinical trial</article-title>. <source>Jama</source> (<year>2018</year>) <volume>320</volume>(<issue>10</issue>):<page-range>984&#x02013;94</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1001/jama.2018.12163</pub-id>
</mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>HK</given-names></name><name><surname>Rombach</surname><given-names>I</given-names></name><name><surname>Zambellas</surname><given-names>R</given-names></name><name><surname>Walker</surname><given-names>AS</given-names></name><name><surname>McNally</surname><given-names>MA</given-names></name><name><surname>Atkins</surname><given-names>BL</given-names></name><etal/></person-group>. <article-title>Oral versus intravenous antibiotics for bone and joint infection</article-title>. <source>N Engl J Med</source> (<year>2019</year>) <volume>380</volume>(<issue>5</issue>):<page-range>425&#x02013;36</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMoa1710926</pub-id>
</mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wong</surname><given-names>HR</given-names></name><name><surname>Wheeler</surname><given-names>DS</given-names></name><name><surname>Tegtmeyer</surname><given-names>K</given-names></name><name><surname>Poynter</surname><given-names>SE</given-names></name><name><surname>Kaplan</surname><given-names>JM</given-names></name><name><surname>Chima</surname><given-names>RS</given-names></name><etal/></person-group>. <article-title>Toward a clinically feasible gene expression-based subclassification strategy for septic shock: Proof of concept</article-title>. <source>Crit Care Med</source> (<year>2010</year>) <volume>38</volume>(<issue>10</issue>):<page-range>1955&#x02013;61</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/CCM.0b013e3181eb924f</pub-id>
</mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wong</surname><given-names>HR</given-names></name><name><surname>Cvijanovich</surname><given-names>NZ</given-names></name><name><surname>Allen</surname><given-names>GL</given-names></name><name><surname>Thomas</surname><given-names>NJ</given-names></name><name><surname>Freishtat</surname><given-names>RJ</given-names></name><name><surname>Anas</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Validation of a gene expression-based subclassification strategy for pediatric septic shock</article-title>. <source>Crit Care Med</source> (<year>2011</year>) <volume>39</volume>(<issue>11</issue>):<page-range>2511&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/CCM.0b013e3182257675</pub-id>
</mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wong</surname><given-names>HR</given-names></name><name><surname>Cvijanovich</surname><given-names>NZ</given-names></name><name><surname>Anas</surname><given-names>N</given-names></name><name><surname>Allen</surname><given-names>GL</given-names></name><name><surname>Thomas</surname><given-names>NJ</given-names></name><name><surname>Bigham</surname><given-names>MT</given-names></name><etal/></person-group>. <article-title>Developing a clinically feasible personalized medicine approach to pediatric septic shock</article-title>. <source>Am J Respir Crit Care Med</source> (<year>2015</year>) <volume>191</volume>(<issue>3</issue>):<page-range>309&#x02013;15</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1164/rccm.201410-1864OC</pub-id>
</mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taylor</surname><given-names>SP</given-names></name><name><surname>Bray</surname><given-names>BC</given-names></name><name><surname>Chou</surname><given-names>SH</given-names></name><name><surname>Burns</surname><given-names>R</given-names></name><name><surname>Kowalkowski</surname><given-names>MA</given-names></name></person-group>. <article-title>Clinical subtypes of sepsis survivors predict readmission and mortality after hospital discharge</article-title>. <source>Ann Am Thorac Soc</source> (<year>2022</year>) <volume>19</volume>(<issue>8</issue>):<page-range>1355&#x02013;63</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1513/AnnalsATS.202109-1088OC</pub-id>
</mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Puthucheary</surname><given-names>ZA</given-names></name><name><surname>Gensichen</surname><given-names>JS</given-names></name><name><surname>Cakiroglu</surname><given-names>AS</given-names></name><name><surname>Cashmore</surname><given-names>R</given-names></name><name><surname>Edbrooke</surname><given-names>L</given-names></name><name><surname>Heintze</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Implications for post critical illness trial design: Sub-phenotyping trajectories of functional recovery among sepsis survivors</article-title>. <source>Crit Care (London England)</source> (<year>2020</year>) <volume>24</volume>(<issue>1</issue>):<fpage>577</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s13054-020-03275-w</pub-id>
</mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soussi</surname><given-names>S</given-names></name><name><surname>Sharma</surname><given-names>D</given-names></name><name><surname>Juni</surname><given-names>P</given-names></name><name><surname>Lebovic</surname><given-names>G</given-names></name><name><surname>Brochard</surname><given-names>L</given-names></name><name><surname>Marshall</surname><given-names>JC</given-names></name><etal/></person-group>. <article-title>Identifying clinical subtypes in sepsis-survivors with different one-year outcomes: A secondary latent class analysis of the frog-icu cohort</article-title>. <source>Crit Care (London England)</source> (<year>2022</year>) <volume>26</volume>(<issue>1</issue>):<fpage>114</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s13054-022-03972-8</pub-id>
</mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Han</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>T</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Analysis of the correlation between the longitudinal trajectory of sofa scores and prognosis in patients with sepsis at 72 hour after admission based on group trajectory modeling</article-title>. <source>J Intensive Med</source> (<year>2022</year>) <volume>2</volume>(<issue>1</issue>):<fpage>39</fpage>&#x02013;<lpage>49</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jointm.2021.11.001</pub-id>
<pub-id pub-id-type="pmid">36789228</pub-id>
</mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iwashyna</surname><given-names>TJ</given-names></name><name><surname>Ely</surname><given-names>EW</given-names></name><name><surname>Smith</surname><given-names>DM</given-names></name><name><surname>Langa</surname><given-names>KM</given-names></name></person-group>. <article-title>Long-term cognitive impairment and functional disability among survivors of severe sepsis</article-title>. <source>Jama</source> (<year>2010</year>) <volume>304</volume>(<issue>16</issue>):<page-range>1787&#x02013;94</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1001/jama.2010.1553</pub-id>
</mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Herridge</surname><given-names>MS</given-names></name><name><surname>Tansey</surname><given-names>CM</given-names></name><name><surname>Matte</surname><given-names>A</given-names></name><name><surname>Tomlinson</surname><given-names>G</given-names></name><name><surname>Diaz-Granados</surname><given-names>N</given-names></name><name><surname>Cooper</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Functional disability 5 years after acute respiratory distress syndrome</article-title>. <source>N Engl J Med</source> (<year>2011</year>) <volume>364</volume>(<issue>14</issue>):<page-range>1293&#x02013;304</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMoa1011802</pub-id>
</mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boede</surname><given-names>M</given-names></name><name><surname>Gensichen</surname><given-names>JS</given-names></name><name><surname>Jackson</surname><given-names>JC</given-names></name><name><surname>Eissler</surname><given-names>F</given-names></name><name><surname>Lehmann</surname><given-names>T</given-names></name><name><surname>Schulz</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Trajectories of depression in sepsis survivors: An observational cohort study</article-title>. <source>Crit Care (London England)</source> (<year>2021</year>) <volume>25</volume>(<issue>1</issue>):<fpage>161</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s13054-021-03577-7</pub-id>
</mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>K</given-names></name><name><surname>Worrack</surname><given-names>S</given-names></name><name><surname>Von Korff</surname><given-names>M</given-names></name><name><surname>Davydow</surname><given-names>D</given-names></name><name><surname>Brunkhorst</surname><given-names>F</given-names></name><name><surname>Ehlert</surname><given-names>U</given-names></name><etal/></person-group>. <article-title>Effect of a primary care management intervention on mental health-related quality of life among survivors of sepsis: A randomized clinical trial</article-title>. <source>Jama</source> (<year>2016</year>) <volume>315</volume>(<issue>24</issue>):<page-range>2703&#x02013;11</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1001/jama.2016.7207</pub-id>
</mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>KF</given-names></name><name><surname>Schwarzkopf</surname><given-names>D</given-names></name><name><surname>Baldwin</surname><given-names>LM</given-names></name><name><surname>Brunkhorst</surname><given-names>FM</given-names></name><name><surname>Freytag</surname><given-names>A</given-names></name><name><surname>Heintze</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Long-term courses of sepsis survivors: Effects of a primary care management intervention</article-title>. <source>Am J Med</source> (<year>2020</year>) <volume>133</volume>(<issue>3</issue>):<fpage>381</fpage>&#x02013;<lpage>5 e5</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.amjmed.2019.08.033</pub-id>
<pub-id pub-id-type="pmid">31521666</pub-id>
</mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>K</given-names></name><name><surname>Thiel</surname><given-names>P</given-names></name><name><surname>Mueller</surname><given-names>F</given-names></name><name><surname>Schmuecker</surname><given-names>K</given-names></name><name><surname>Worrack</surname><given-names>S</given-names></name><name><surname>Mehlhorn</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Sepsis survivors monitoring and coordination in outpatient health care (Smooth): Study protocol for a randomized controlled trial</article-title>. <source>Trials</source> (<year>2014</year>) <volume>15</volume>:<elocation-id>283</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/1745-6215-15-283</pub-id>
<pub-id pub-id-type="pmid">25015838</pub-id>
</mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cai</surname><given-names>D</given-names></name><name><surname>Greco</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name></person-group>. <article-title>Sepsis-induced coagulopathy subphenotype identification by latent class analysis</article-title>. <source>Balkan Med J</source> (<year>2023</year>) <volume>40</volume>(<issue>4</issue>):<page-range>244&#x02013;51</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4274/balkanmedj.galenos.2023.2023-4-6</pub-id>
</mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>JZ</given-names></name><name><surname>Ng</surname><given-names>MK</given-names></name><name><surname>Rong</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name></person-group>. <article-title>Automated variable weighting in k-means type clustering</article-title>. <source>IEEE Trans Pattern Anal Mach Intell</source> (<year>2005</year>) <volume>27</volume>(<issue>5</issue>):<page-range>657&#x02013;68</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1109/TPAMI.2005.95</pub-id>
</mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>R</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Clinical phenotyping of septic shock with latent profile analysis: A retrospective multicenter study</article-title>. <source>J Crit Care</source> (<year>2025</year>) <volume>85</volume>:<elocation-id>154932</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jcrc.2024.154932</pub-id>
<pub-id pub-id-type="pmid">39432929</pub-id>
</mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Mo</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>A decision tree model to help treatment decision-making for severe spontaneous intracerebral hemorrhage</article-title>. <source>Int J Surg</source> (<year>2024</year>) <volume>110</volume>(<issue>2</issue>):<page-range>788&#x02013;98</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/JS9.0000000000000852</pub-id>
</mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Lei</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Mao</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Prediction of sepsis among patients with major trauma using artificial intelligence: A multicenter validated cohort study</article-title>. <source>Int J Surg</source> (<year>2024</year>) <volume>111</volume>(<issue>1</issue>):<page-range>467&#x02013;80</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/JS9.0000000000001866</pub-id>
</mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Michelson</surname><given-names>AP</given-names></name><name><surname>Oh</surname><given-names>I</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Puri</surname><given-names>V</given-names></name><name><surname>Kreisel</surname><given-names>D</given-names></name><name><surname>Gelman</surname><given-names>AE</given-names></name><etal/></person-group>. <article-title>Developing machine learning models to predict primary graft dysfunction after lung transplantation</article-title>. <source>Am J Transplant</source> (<year>2024</year>) <volume>24</volume>(<issue>3</issue>):<page-range>458&#x02013;67</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ajt.2023.07.008</pub-id>
</mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dieckhaus</surname><given-names>H</given-names></name><name><surname>Brocidiacono</surname><given-names>M</given-names></name><name><surname>Randolph</surname><given-names>NZ</given-names></name><name><surname>Kuhlman</surname><given-names>B</given-names></name></person-group>. <article-title>Transfer learning to leverage larger datasets for improved prediction of protein stability changes</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2024</year>) <volume>121</volume>(<issue>6</issue>):<fpage>e2314853121</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1073/pnas.2314853121</pub-id>
<pub-id pub-id-type="pmid">38285937</pub-id>
</mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van den Berg</surname><given-names>MAM</given-names></name><name><surname>Medina</surname><given-names>O</given-names></name><name><surname>Loohuis</surname><given-names>IIP</given-names></name><name><surname>van der Flier</surname><given-names>MM</given-names></name><name><surname>Dudink</surname><given-names>JJ</given-names></name><name><surname>Benders</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Development and clinical impact assessment of a machine-learning model for early prediction of late-onset sepsis</article-title>. <source>Comput Biol Med</source> (<year>2023</year>) <volume>163</volume>:<elocation-id>107156</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.compbiomed.2023.107156</pub-id>
<pub-id pub-id-type="pmid">37369173</pub-id>
</mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhavani</surname><given-names>SV</given-names></name><name><surname>Xiong</surname><given-names>L</given-names></name><name><surname>Pius</surname><given-names>A</given-names></name><name><surname>Semler</surname><given-names>M</given-names></name><name><surname>Qian</surname><given-names>ET</given-names></name><name><surname>Verhoef</surname><given-names>PA</given-names></name><etal/></person-group>. <article-title>Comparison of time series clustering methods for identifying novel subphenotypes of patients with infection</article-title>. <source>J Am Med Inform Assoc</source> (<year>2023</year>) <volume>30</volume>(<issue>6</issue>):<page-range>1158&#x02013;66</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/jamia/ocad063</pub-id>
</mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wong</surname><given-names>KC</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name></person-group>. <article-title>Evolutionary multiobjective clustering algorithms with ensemble for patient stratification</article-title>. <source>IEEE Trans Cybern</source> (<year>2022</year>) <volume>52</volume>(<issue>10</issue>):<page-range>11027&#x02013;40</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1109/TCYB.2021.3069434</pub-id>
</mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kijpaisalratana</surname><given-names>N</given-names></name><name><surname>Sanglertsinlapachai</surname><given-names>D</given-names></name><name><surname>Techaratsami</surname><given-names>S</given-names></name><name><surname>Musikatavorn</surname><given-names>K</given-names></name><name><surname>Saoraya</surname><given-names>J</given-names></name></person-group>. <article-title>Machine learning algorithms for early sepsis detection in the emergency department: A retrospective study</article-title>. <source>Int J Med Inform</source> (<year>2022</year>) <volume>160</volume>:<elocation-id>104689</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ijmedinf.2022.104689</pub-id>
<pub-id pub-id-type="pmid">35078027</pub-id>
</mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Zuani</surname><given-names>M</given-names></name><name><surname>Hortova-Kohoutkova</surname><given-names>M</given-names></name><name><surname>Andrejcinova</surname><given-names>I</given-names></name><name><surname>Tomaskova</surname><given-names>V</given-names></name><name><surname>Sramek</surname><given-names>V</given-names></name><name><surname>Helan</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Human myeloid-derived suppressor cell expansion during sepsis is revealed by unsupervised clustering of flow cytometric data</article-title>. <source>Eur J Immunol</source> (<year>2021</year>) <volume>51</volume>(<issue>7</issue>):<page-range>1785&#x02013;91</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/eji.202049141</pub-id>
</mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lauritsen</surname><given-names>SM</given-names></name><name><surname>Kalor</surname><given-names>ME</given-names></name><name><surname>Kongsgaard</surname><given-names>EL</given-names></name><name><surname>Lauritsen</surname><given-names>KM</given-names></name><name><surname>Jorgensen</surname><given-names>MJ</given-names></name><name><surname>Lange</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Early detection of sepsis utilizing deep learning on electronic health record event sequences</article-title>. <source>Artif Intell Med</source> (<year>2020</year>) <volume>104</volume>:<elocation-id>101820</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.artmed.2020.101820</pub-id>
<pub-id pub-id-type="pmid">32498999</pub-id>
</mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Turki</surname><given-names>T</given-names></name><name><surname>Wei</surname><given-names>Z</given-names></name></person-group>. <article-title>Boosting support vector machines for cancer discrimination tasks</article-title>. <source>Comput Biol Med</source> (<year>2018</year>) <volume>101</volume>:<page-range>236&#x02013;49</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.compbiomed.2018.08.006</pub-id>
</mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Loftus</surname><given-names>TJ</given-names></name><name><surname>Brakenridge</surname><given-names>SC</given-names></name><name><surname>Croft</surname><given-names>CA</given-names></name><name><surname>Smith</surname><given-names>RS</given-names></name><name><surname>Efron</surname><given-names>PA</given-names></name><name><surname>Moore</surname><given-names>FA</given-names></name><etal/></person-group>. <article-title>Neural network prediction of severe lower intestinal bleeding and the need for surgical intervention</article-title>. <source>J Surg Res</source> (<year>2017</year>) <volume>212</volume>:<page-range>42&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jss.2016.12.032</pub-id>
</mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Hao</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>The application of artificial intelligence in the management of sepsis</article-title>. <source>Med Rev (2021)</source> (<year>2023</year>) <volume>3</volume>(<issue>5</issue>):<page-range>369&#x02013;80</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1515/mr-2023-0039</pub-id>
</mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Hao</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>T</given-names></name></person-group>. <article-title>Knowledge mapping and research hotspots of artificial intelligence on icu and anesthesia: From a global bibliometric perspective</article-title>. <source>Anesthesiology Perioperative Sci</source> (<year>2023</year>) <volume>1</volume>(<issue>4</issue>). doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s44254-023-00031-5</pub-id>
</mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>T</given-names></name><name><surname>Lang</surname><given-names>X</given-names></name><name><surname>Jia</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Inhibiting DNA methylation improves survival in severe sepsis by regulating nf-kappab pathway</article-title>. <source>Front Immunol</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>1360</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2020.01360</pub-id>
<pub-id pub-id-type="pmid">32714333</pub-id>
</mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Falcao-Holanda</surname><given-names>RB</given-names></name><name><surname>Brunialti</surname><given-names>MKC</given-names></name><name><surname>Jasiulionis</surname><given-names>MG</given-names></name><name><surname>Salomao</surname><given-names>R</given-names></name></person-group>. <article-title>Epigenetic regulation in sepsis, role in pathophysiology and therapeutic perspective</article-title>. <source>Front Med</source> (<year>2021</year>) <volume>8</volume>:<elocation-id>685333</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fmed.2021.685333</pub-id>
</mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davenport</surname><given-names>EE</given-names></name><name><surname>Burnham</surname><given-names>KL</given-names></name><name><surname>Radhakrishnan</surname><given-names>J</given-names></name><name><surname>Humburg</surname><given-names>P</given-names></name><name><surname>Hutton</surname><given-names>P</given-names></name><name><surname>Mills</surname><given-names>TC</given-names></name><etal/></person-group>. <article-title>Genomic landscape of the individual host response and outcomes in sepsis: A prospective cohort study</article-title>. <source>Lancet Respir Med</source> (<year>2016</year>) <volume>4</volume>(<issue>4</issue>):<page-range>259&#x02013;71</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S2213-2600(16)00046-1</pub-id>
</mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scicluna</surname><given-names>BP</given-names></name><name><surname>van Vught</surname><given-names>LA</given-names></name><name><surname>Zwinderman</surname><given-names>AH</given-names></name><name><surname>Wiewel</surname><given-names>MA</given-names></name><name><surname>Davenport</surname><given-names>EE</given-names></name><name><surname>Burnham</surname><given-names>KL</given-names></name><etal/></person-group>. <article-title>Classification of patients with sepsis according to blood genomic endotype: A prospective cohort study</article-title>. <source>Lancet Respir Med</source> (<year>2017</year>) <volume>5</volume>(<issue>10</issue>):<page-range>816&#x02013;26</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S2213-2600(17)30294-1</pub-id>
</mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cajander</surname><given-names>S</given-names></name><name><surname>Kox</surname><given-names>M</given-names></name><name><surname>Scicluna</surname><given-names>BP</given-names></name><name><surname>Weigand</surname><given-names>MA</given-names></name><name><surname>Mora</surname><given-names>RA</given-names></name><name><surname>Flohe</surname><given-names>SB</given-names></name><etal/></person-group>. <article-title>Profiling the dysregulated immune response in sepsis: Overcoming challenges to achieve the goal of precision medicine</article-title>. <source>Lancet Respir Med</source> (<year>2024</year>) <volume>12</volume>(<issue>4</issue>):<page-range>305&#x02013;22</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S2213-2600(23)00330-2</pub-id>
</mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burnham</surname><given-names>KL</given-names></name><name><surname>Davenport</surname><given-names>EE</given-names></name><name><surname>Radhakrishnan</surname><given-names>J</given-names></name><name><surname>Humburg</surname><given-names>P</given-names></name><name><surname>Gordon</surname><given-names>AC</given-names></name><name><surname>Hutton</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Shared and distinct aspects of the sepsis transcriptomic response to fecal peritonitis and pneumonia</article-title>. <source>Am J Respir Crit Care Med</source> (<year>2017</year>) <volume>196</volume>(<issue>3</issue>):<page-range>328&#x02013;39</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1164/rccm.201608-1685OC</pub-id>
</mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>David</surname><given-names>B</given-names></name><name><surname>Antcliffe</surname><given-names>KLB</given-names></name><name><surname>Al-Beidh</surname><given-names>F</given-names></name><name><surname>Santhakumaran</surname><given-names>S</given-names></name><name><surname>Brett</surname><given-names>SJ</given-names></name><name><surname>Hinds</surname><given-names>CJ</given-names></name><etal/></person-group>. <article-title>Erratum: Transcriptomic signatures in sepsis and a differential response to steroids. from the vanish randomized trial</article-title>. <source>Am J Respir Crit Care Med</source> (<year>2022</year>) <volume>206</volume>(<issue>12</issue>):<page-range>1572&#x02013;3</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1164/rccm.v206erratum10</pub-id>
</mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mantel</surname><given-names>I</given-names></name><name><surname>Sadiq</surname><given-names>BA</given-names></name><name><surname>Blander</surname><given-names>JM</given-names></name></person-group>. <article-title>Spotlight on tap and its vital role in antigen presentation and cross-presentation</article-title>. <source>Mol Immunol</source> (<year>2022</year>) <volume>142</volume>:<page-range>105&#x02013;19</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.molimm.2021.12.013</pub-id>
</mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Ge</surname><given-names>H</given-names></name><name><surname>Xing</surname><given-names>L</given-names></name><name><surname>Hong</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name></person-group>. <article-title>Deep learning-based clustering robustly identified two classes of sepsis with both prognostic and predictive values</article-title>. <source>EBioMedicine</source> (<year>2020</year>) <volume>62</volume>:<elocation-id>103081</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ebiom.2020.103081</pub-id>
<pub-id pub-id-type="pmid">33181462</pub-id>
</mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cohen</surname><given-names>J</given-names></name><name><surname>Blumenthal</surname><given-names>A</given-names></name><name><surname>Cuellar-Partida</surname><given-names>G</given-names></name><name><surname>Evans</surname><given-names>DM</given-names></name><name><surname>Finfer</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>The relationship between adrenocortical candidate gene expression and clinical response to hydrocortisone in patients with septic shock</article-title>. <source>Intensive Care Med</source> (<year>2021</year>) <volume>47</volume>(<issue>9</issue>):<page-range>974&#x02013;83</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00134-021-06464-5</pub-id>
</mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sweeney</surname><given-names>TE</given-names></name><name><surname>Azad</surname><given-names>TD</given-names></name><name><surname>Donato</surname><given-names>M</given-names></name><name><surname>Haynes</surname><given-names>WA</given-names></name><name><surname>Perumal</surname><given-names>TM</given-names></name><name><surname>Henao</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters</article-title>. <source>Crit Care Med</source> (<year>2018</year>) <volume>46</volume>(<issue>6</issue>):<page-range>915&#x02013;25</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/CCM.0000000000003084</pub-id>
</mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sweeney</surname><given-names>TE</given-names></name><name><surname>Liesenfeld</surname><given-names>O</given-names></name><name><surname>Wacker</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>YD</given-names></name><name><surname>Rawling</surname><given-names>D</given-names></name><name><surname>Remmel</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Validation of inflammopathic, adaptive, and coagulopathic sepsis endotypes in coronavirus disease 2019</article-title>. <source>Crit Care Med</source> (<year>2021</year>) <volume>49</volume>(<issue>2</issue>):<page-range>e170&#x02013;e8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/CCM.0000000000004786</pub-id>
</mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yao</surname><given-names>L</given-names></name><name><surname>Rey</surname><given-names>DA</given-names></name><name><surname>Bulgarelli</surname><given-names>L</given-names></name><name><surname>Kast</surname><given-names>R</given-names></name><name><surname>Osborn</surname><given-names>J</given-names></name><name><surname>Van Ark</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Gene expression scoring of immune activity levels for precision use of hydrocortisone in vasodilatory shock</article-title>. <source>Shock</source> (<year>2022</year>) <volume>57</volume>(<issue>3</issue>):<page-range>384&#x02013;91</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/SHK.0000000000001910</pub-id>
</mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Chang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Classification of patients with sepsis according to immune cell characteristics: A bioinformatic analysis of two cohort studies</article-title>. <source>Front Med</source> (<year>2020</year>) <volume>7</volume>:<elocation-id>598652</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fmed.2020.598652</pub-id>
</mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marshall</surname><given-names>JC</given-names></name></person-group>. <article-title>Why have clinical trials in sepsis failed</article-title>? <source>Trends Mol Med</source> (<year>2014</year>) <volume>20</volume>(<issue>4</issue>):<fpage>195</fpage>&#x02013;<lpage>203</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.molmed.2014.01.007</pub-id>
<pub-id pub-id-type="pmid">24581450</pub-id>
</mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stanski</surname><given-names>NL</given-names></name><name><surname>Wong</surname><given-names>HR</given-names></name></person-group>. <article-title>Prognostic and predictive enrichment in sepsis</article-title>. <source>Nat Rev Nephrol</source> (<year>2020</year>) <volume>16</volume>(<issue>1</issue>):<fpage>20</fpage>&#x02013;<lpage>31</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41581-019-0199-3</pub-id>
<pub-id pub-id-type="pmid">31511662</pub-id>
</mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mi</surname><given-names>Y</given-names></name><name><surname>Burnham</surname><given-names>KL</given-names></name><name><surname>Charles</surname><given-names>PD</given-names></name><name><surname>Heilig</surname><given-names>R</given-names></name><name><surname>Vendrell</surname><given-names>I</given-names></name><name><surname>Whalley</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>High-throughput mass spectrometry maps the sepsis plasma proteome and differences in patient response</article-title>. <source>Sci Transl Med</source> (<year>2024</year>) <volume>16</volume>(<issue>750</issue>):<elocation-id>eadh0185</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1126/scitranslmed.adh0185</pub-id>
<pub-id pub-id-type="pmid">38838133</pub-id>
</mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yehya</surname><given-names>N</given-names></name><name><surname>Fazelinia</surname><given-names>H</given-names></name><name><surname>Taylor</surname><given-names>DM</given-names></name><name><surname>Lawrence</surname><given-names>GG</given-names></name><name><surname>Spruce</surname><given-names>LA</given-names></name><name><surname>Thompson</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Differentiating children with sepsis with and without acute respiratory distress syndrome using proteomics</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> (<year>2022</year>) <volume>322</volume>(<issue>3</issue>):<page-range>L365&#x02013;L72</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1152/ajplung.00164.2021</pub-id>
</mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Long</surname><given-names>G</given-names></name><name><surname>Luo</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Shang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>S100a8/A9: An emerging player in sepsis and sepsis-induced organ injury</article-title>. <source>Biomedicine Pharmacotherapy = Biomedecine Pharmacotherapie</source> (<year>2023</year>) <volume>168</volume>:<elocation-id>115674</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.biopha.2023.115674</pub-id>
<pub-id pub-id-type="pmid">37812889</pub-id>
</mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mickiewicz</surname><given-names>B</given-names></name><name><surname>Thompson</surname><given-names>GC</given-names></name><name><surname>Blackwood</surname><given-names>J</given-names></name><name><surname>Jenne</surname><given-names>CN</given-names></name><name><surname>Winston</surname><given-names>BW</given-names></name><name><surname>Vogel</surname><given-names>HJ</given-names></name><etal/></person-group>. <article-title>Development of metabolic and inflammatory mediator biomarker phenotyping for early diagnosis and triage of pediatric sepsis</article-title>. <source>Crit Care (London England)</source> (<year>2015</year>) <volume>19</volume>(<issue>1</issue>):<fpage>320</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s13054-015-1026-2</pub-id>
</mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Yin</surname><given-names>P</given-names></name><name><surname>Amathieu</surname><given-names>R</given-names></name><name><surname>Savarin</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name></person-group>. <article-title>Application of lc-Ms-Based metabolomics method in differentiating septic survivors from non-survivors</article-title>. <source>Anal Bioanal Chem</source> (<year>2016</year>) <volume>408</volume>(<issue>27</issue>):<page-range>7641&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00216-016-9845-9</pub-id>
</mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reisinger</surname><given-names>AC</given-names></name><name><surname>Posch</surname><given-names>F</given-names></name><name><surname>Hackl</surname><given-names>G</given-names></name><name><surname>Marsche</surname><given-names>G</given-names></name><name><surname>Sourij</surname><given-names>H</given-names></name><name><surname>Bourgeois</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Branched-chain amino acids can predict mortality in icu sepsis patients</article-title>. <source>Nutrients</source> (<year>2021</year>) <volume>13</volume>(<issue>9</issue>). doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/nu13093106</pub-id>
</mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Triba</surname><given-names>MN</given-names></name><name><surname>Amathieu</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Bouchemal</surname><given-names>N</given-names></name><name><surname>Hantz</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Nuclear magnetic resonance-based serum metabolomic analysis reveals different disease evolution profiles between septic shock survivors and non-survivors</article-title>. <source>Crit Care (London England)</source> (<year>2019</year>) <volume>23</volume>(<issue>1</issue>):<fpage>169</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s13054-019-2456-z</pub-id>
</mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Teng</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>K</given-names></name></person-group>. <article-title>Prediction of sepsis mortality using metabolite biomarkers in the blood: A meta-analysis of death-related pathways and prospective validation</article-title>. <source>BMC Med</source> (<year>2020</year>) <volume>18</volume>(<issue>1</issue>):<fpage>83</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12916-020-01546-5</pub-id>
<pub-id pub-id-type="pmid">32290837</pub-id>
</mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>MS</given-names></name><name><surname>Park</surname><given-names>BH</given-names></name><name><surname>Jung</surname><given-names>WJ</given-names></name><name><surname>Lee</surname><given-names>IS</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><etal/></person-group>. <article-title>Prognostic implications of serum lipid metabolism over time during sepsis</article-title>. <source>BioMed Res Int</source> (<year>2015</year>) <volume>2015</volume>:<elocation-id>789298</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1155/2015/789298</pub-id>
<pub-id pub-id-type="pmid">26351639</pub-id>
</mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khaliq</surname><given-names>W</given-names></name><name><surname>Grossmann</surname><given-names>P</given-names></name><name><surname>Neugebauer</surname><given-names>S</given-names></name><name><surname>Kleyman</surname><given-names>A</given-names></name><name><surname>Domizi</surname><given-names>R</given-names></name><name><surname>Calcinaro</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Lipid metabolic signatures deviate in sepsis survivors compared to non-survivors</article-title>. <source>Comput Struct Biotechnol J</source> (<year>2020</year>) <volume>18</volume>:<page-range>3678&#x02013;91</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.csbj.2020.11.009</pub-id>
</mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cirstea</surname><given-names>M</given-names></name><name><surname>Walley</surname><given-names>KR</given-names></name><name><surname>Russell</surname><given-names>JA</given-names></name><name><surname>Brunham</surname><given-names>LR</given-names></name><name><surname>Genga</surname><given-names>KR</given-names></name><name><surname>Boyd</surname><given-names>JH</given-names></name></person-group>. <article-title>Decreased high-density lipoprotein cholesterol level is an early prognostic marker for organ dysfunction and death in patients with suspected sepsis</article-title>. <source>J Crit Care</source> (<year>2017</year>) <volume>38</volume>:<page-range>289&#x02013;94</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jcrc.2016.11.041</pub-id>
</mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dalli</surname><given-names>J</given-names></name><name><surname>Colas</surname><given-names>RA</given-names></name><name><surname>Quintana</surname><given-names>C</given-names></name><name><surname>Barragan-Bradford</surname><given-names>D</given-names></name><name><surname>Hurwitz</surname><given-names>S</given-names></name><name><surname>Levy</surname><given-names>BD</given-names></name><etal/></person-group>. <article-title>Human sepsis eicosanoid and proresolving lipid mediator temporal profiles: Correlations with survival and clinical outcomes</article-title>. <source>Crit Care Med</source> (<year>2017</year>) <volume>45</volume>(<issue>1</issue>):<fpage>58</fpage>&#x02013;<lpage>68</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/CCM.0000000000002014</pub-id>
<pub-id pub-id-type="pmid">27632672</pub-id>
</mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lodge</surname><given-names>S</given-names></name><name><surname>Litton</surname><given-names>E</given-names></name><name><surname>Gray</surname><given-names>N</given-names></name><name><surname>Ryan</surname><given-names>M</given-names></name><name><surname>Millet</surname><given-names>O</given-names></name><name><surname>Fear</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Stratification of sepsis patients on admission into the intensive care unit according to differential plasma metabolic phenotypes</article-title>. <source>J Proteome Res</source> (<year>2024</year>) <volume>23</volume>(<issue>4</issue>):<page-range>1328&#x02013;40</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1021/acs.jproteome.3c00803</pub-id>
</mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Ruan</surname><given-names>Z</given-names></name><name><surname>Pan</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Identifying septic shock subgroups to tailor fluid strategies through multi-omics integration</article-title>. <source>Nat Commun</source> (<year>2024</year>) <volume>15</volume>(<issue>1</issue>):<fpage>9028</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41467-024-53239-9</pub-id>
<pub-id pub-id-type="pmid">39424794</pub-id>
</mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Integrative analysis of metabolomics and proteomics reveals amino acid metabolism disorder in sepsis</article-title>. <source>J Trans Med</source> (<year>2022</year>) <volume>20</volume>(<issue>1</issue>):<fpage>123</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12967-022-03320-y</pub-id>
</mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ke</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name></person-group>. <article-title>Interpretable machine learning to optimize early in-hospital mortality prediction for elderly patients with sepsis: A discovery study</article-title>. <source>Comput Math Methods Med</source> (<year>2022</year>) <volume>2022</volume>:<elocation-id>4820464</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1155/2022/4820464</pub-id>
<pub-id pub-id-type="pmid">36570336</pub-id>
</mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name><surname>Aschenbrenner</surname><given-names>AC</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><name><surname>Bock</surname><given-names>C</given-names></name><name><surname>Calandra</surname><given-names>T</given-names></name><name><surname>Gat-Viks</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>The pathophysiology of sepsis and precision-Medicine-Based immunotherapy</article-title>. <source>Nat Immunol</source> (<year>2024</year>) <volume>25</volume>(<issue>1</issue>):<fpage>19</fpage>&#x02013;<lpage>28</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41590-023-01660-5</pub-id>
<pub-id pub-id-type="pmid">38168953</pub-id>
</mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vranas</surname><given-names>KC</given-names></name><name><surname>Jopling</surname><given-names>JK</given-names></name><name><surname>Sweeney</surname><given-names>TE</given-names></name><name><surname>Ramsey</surname><given-names>MC</given-names></name><name><surname>Milstein</surname><given-names>AS</given-names></name><name><surname>Slatore</surname><given-names>CG</given-names></name><etal/></person-group>. <article-title>Identifying distinct subgroups of icu patients: A machine learning approach</article-title>. <source>Crit Care Med</source> (<year>2017</year>) <volume>45</volume>(<issue>10</issue>):<page-range>1607&#x02013;15</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/CCM.0000000000002548</pub-id>
</mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Castela Forte</surname><given-names>J</given-names></name><name><surname>Perner</surname><given-names>A</given-names></name><name><surname>van der Horst</surname><given-names>ICC</given-names></name></person-group>. <article-title>The use of clustering algorithms in critical care research to unravel patient heterogeneity</article-title>. <source>Intensive Care Med</source> (<year>2019</year>) <volume>45</volume>(<issue>7</issue>):<page-range>1025&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00134-019-05631-z</pub-id>
</mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhavani</surname><given-names>SV</given-names></name><name><surname>Semler</surname><given-names>M</given-names></name><name><surname>Qian</surname><given-names>ET</given-names></name><name><surname>Verhoef</surname><given-names>PA</given-names></name><name><surname>Robichaux</surname><given-names>C</given-names></name><name><surname>Churpek</surname><given-names>MM</given-names></name><etal/></person-group>. <article-title>Development and validation of novel sepsis subphenotypes using trajectories of vital signs</article-title>. <source>Intensive Care Med</source> (<year>2022</year>) <volume>48</volume>(<issue>11</issue>):<page-range>1582&#x02013;92</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00134-022-06890-z</pub-id>
</mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Semler</surname><given-names>MW</given-names></name><name><surname>Self</surname><given-names>WH</given-names></name><name><surname>Wanderer</surname><given-names>JP</given-names></name><name><surname>Ehrenfeld</surname><given-names>JM</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Byrne</surname><given-names>DW</given-names></name><etal/></person-group>. <article-title>Balanced crystalloids versus saline in critically ill adults</article-title>. <source>N Engl J Med</source> (<year>2018</year>) <volume>378</volume>(<issue>9</issue>):<page-range>829&#x02013;39</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMoa1711584</pub-id>
</mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Komorowski</surname><given-names>M</given-names></name><name><surname>Green</surname><given-names>A</given-names></name><name><surname>Tatham</surname><given-names>KC</given-names></name><name><surname>Seymour</surname><given-names>C</given-names></name><name><surname>Antcliffe</surname><given-names>D</given-names></name></person-group>. <article-title>Sepsis biomarkers and diagnostic tools with a focus on machine learning</article-title>. <source>EBioMedicine</source> (<year>2022</year>) <volume>86</volume>:<elocation-id>104394</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ebiom.2022.104394</pub-id>
<pub-id pub-id-type="pmid">36470834</pub-id>
</mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Taweesedt</surname><given-names>PT</given-names></name><name><surname>Surani</surname><given-names>S</given-names></name></person-group>. <article-title>Utilizing artificial intelligence in critical care: Adding a handy tool to our armamentarium</article-title>. <source>Cureus</source> (<year>2021</year>) <volume>13</volume>(<issue>6</issue>):<elocation-id>e15531</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.7759/cureus.15531</pub-id>
<pub-id pub-id-type="pmid">34268051</pub-id>
</mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qin</surname><given-names>Y</given-names></name><name><surname>Caldino Bohn</surname><given-names>RI</given-names></name><name><surname>Sriram</surname><given-names>A</given-names></name><name><surname>Kernan</surname><given-names>KF</given-names></name><name><surname>Carcillo</surname><given-names>JA</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Refining empiric subgroups of pediatric sepsis using machine-learning techniques on observational data</article-title>. <source>Front Pediatr</source> (<year>2023</year>) <volume>11</volume>:<elocation-id>1035576</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fped.2023.1035576</pub-id>
<pub-id pub-id-type="pmid">36793336</pub-id>
</mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Knox</surname><given-names>DB</given-names></name><name><surname>Lanspa</surname><given-names>MJ</given-names></name><name><surname>Kuttler</surname><given-names>KG</given-names></name><name><surname>Brewer</surname><given-names>SC</given-names></name><name><surname>Brown</surname><given-names>SM</given-names></name></person-group>. <article-title>Phenotypic clusters within sepsis-associated multiple organ dysfunction syndrome</article-title>. <source>Intensive Care Med</source> (<year>2015</year>) <volume>41</volume>(<issue>5</issue>):<page-range>814&#x02013;22</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00134-015-3764-7</pub-id>
</mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seymour</surname><given-names>CW</given-names></name><name><surname>Kennedy</surname><given-names>JN</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>CH</given-names></name><name><surname>Elliott</surname><given-names>CF</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis</article-title>. <source>Jama</source> (<year>2019</year>) <volume>321</volume>(<issue>20</issue>):<page-range>2003&#x02013;17</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1001/jama.2019.5791</pub-id>
</mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ding</surname><given-names>M</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name></person-group>. <article-title>Unsupervised phenotyping of sepsis using nonnegative matrix factorization of temporal trends from a multivariate panel of physiological measurements</article-title>. <source>BMC Med Inform Decis Mak</source> (<year>2021</year>) <volume>21</volume>(<issue>Suppl 5</issue>):<fpage>95</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12911-021-01460-7</pub-id>
<pub-id pub-id-type="pmid">33836745</pub-id>
</mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Papin</surname><given-names>G</given-names></name><name><surname>Bailly</surname><given-names>S</given-names></name><name><surname>Dupuis</surname><given-names>C</given-names></name><name><surname>Ruckly</surname><given-names>S</given-names></name><name><surname>Gainnier</surname><given-names>M</given-names></name><name><surname>Argaud</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Clinical and biological clusters of sepsis patients using hierarchical clustering</article-title>. <source>PloS One</source> (<year>2021</year>) <volume>16</volume>(<issue>8</issue>):<elocation-id>e0252793</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1371/journal.pone.0252793</pub-id>
<pub-id pub-id-type="pmid">34347776</pub-id>
</mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>ZM</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Hamoud</surname><given-names>A</given-names></name><name><surname>Stappen</surname><given-names>L</given-names></name><name><surname>Dobson</surname><given-names>RJB</given-names></name><name><surname>Agarossi</surname><given-names>A</given-names></name></person-group>. <article-title>On classifying sepsis heterogeneity in the icu: Insight using machine learning</article-title>. <source>J Am Med Inform Assoc</source> (<year>2020</year>) <volume>27</volume>(<issue>3</issue>):<page-range>437&#x02013;43</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/jamia/ocz211</pub-id>
</mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bernard</surname><given-names>GR</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>Laterre</surname><given-names>PF</given-names></name><name><surname>LaRosa</surname><given-names>SP</given-names></name><name><surname>Dhainaut</surname><given-names>JF</given-names></name><name><surname>Lopez-Rodriguez</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Efficacy and safety of recombinant human activated protein c for severe sepsis</article-title>. <source>N Engl J Med</source> (<year>2001</year>) <volume>344</volume>(<issue>10</issue>):<fpage>699</fpage>&#x02013;<lpage>709</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJM200103083441001</pub-id>
<pub-id pub-id-type="pmid">11236773</pub-id>
</mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Opal</surname><given-names>SM</given-names></name><name><surname>Laterre</surname><given-names>PF</given-names></name><name><surname>Francois</surname><given-names>B</given-names></name><name><surname>LaRosa</surname><given-names>SP</given-names></name><name><surname>Angus</surname><given-names>DC</given-names></name><name><surname>Mira</surname><given-names>JP</given-names></name><etal/></person-group>. <article-title>Effect of eritoran, an antagonist of Md2-Tlr4, on mortality in patients with severe sepsis: The access randomized trial</article-title>. <source>Jama</source> (<year>2013</year>) <volume>309</volume>(<issue>11</issue>):<page-range>1154&#x02013;62</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1001/jama.2013.2194</pub-id>
</mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Knaus</surname><given-names>WA</given-names></name><name><surname>Marks</surname><given-names>RD</given-names></name></person-group>. <article-title>New phenotypes for sepsis: The promise and problem of applying machine learning and artificial intelligence in clinical research</article-title>. <source>Jama</source> (<year>2019</year>) <volume>321</volume>(<issue>20</issue>):<page-range>1981&#x02013;2</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1001/jama.2019.5794</pub-id>
</mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hasegawa</surname><given-names>D</given-names></name><name><surname>Nishida</surname><given-names>O</given-names></name></person-group>. <article-title>Patient selection in sepsis: Precision medicine using phenotypes and its implications for future clinical trial design</article-title>. <source>J Thorac Dis</source> (<year>2019</year>) <volume>11</volume>(<issue>9</issue>):<page-range>3672&#x02013;5</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.21037/jtd.2019.09.31</pub-id>
</mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dahmer</surname><given-names>MK</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Quasney</surname><given-names>MW</given-names></name><name><surname>Sapru</surname><given-names>A</given-names></name><name><surname>Weeks</surname><given-names>HM</given-names></name><etal/></person-group>. <article-title>Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: A latent class analysis</article-title>. <source>Lancet Respir Med</source> (<year>2022</year>) <volume>10</volume>(<issue>3</issue>):<page-range>289&#x02013;97</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S2213-2600(21)00382-9</pub-id>
</mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Mao</surname><given-names>C</given-names></name><name><surname>Su</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Siempos</surname><given-names>I</given-names></name><name><surname>Torres</surname><given-names>LK</given-names></name><etal/></person-group>. <article-title>Sepsis subphenotyping based on organ dysfunction trajectory</article-title>. <source>Crit Care (London England)</source> (<year>2022</year>) <volume>26</volume>(<issue>1</issue>):<fpage>197</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s13054-022-04071-4</pub-id>
</mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhavani</surname><given-names>SV</given-names></name><name><surname>Carey</surname><given-names>KA</given-names></name><name><surname>Gilbert</surname><given-names>ER</given-names></name><name><surname>Afshar</surname><given-names>M</given-names></name><name><surname>Verhoef</surname><given-names>PA</given-names></name><name><surname>Churpek</surname><given-names>MM</given-names></name></person-group>. <article-title>Identifying novel sepsis subphenotypes using temperature trajectories</article-title>. <source>Am J Respir Crit Care Med</source> (<year>2019</year>) <volume>200</volume>(<issue>3</issue>):<page-range>327&#x02013;35</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1164/rccm.201806-1197OC</pub-id>
</mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhavani</surname><given-names>SV</given-names></name><name><surname>Spicer</surname><given-names>A</given-names></name><name><surname>Sinha</surname><given-names>P</given-names></name><name><surname>Malik</surname><given-names>A</given-names></name><name><surname>Lopez-Espina</surname><given-names>C</given-names></name><name><surname>Schmalz</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Distinct immune profiles and clinical outcomes in sepsis subphenotypes based on temperature trajectories</article-title>. <source>Intensive Care Med</source> (<year>2024</year>) <volume>50</volume>(<issue>12</issue>):<page-range>2094&#x02013;104</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00134-024-07669-0</pub-id>
</mixed-citation></ref><ref id="B133"><label>133</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kudo</surname><given-names>D</given-names></name><name><surname>Goto</surname><given-names>T</given-names></name><name><surname>Uchimido</surname><given-names>R</given-names></name><name><surname>Hayakawa</surname><given-names>M</given-names></name><name><surname>Yamakawa</surname><given-names>K</given-names></name><name><surname>Abe</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Coagulation phenotypes in sepsis and effects of recombinant human thrombomodulin: An analysis of three multicentre observational studies</article-title>. <source>Crit Care (London England)</source> (<year>2021</year>) <volume>25</volume>(<issue>1</issue>):<fpage>114</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s13054-021-03541-5</pub-id>
</mixed-citation></ref><ref id="B134"><label>134</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Papathanakos</surname><given-names>G</given-names></name><name><surname>Andrianopoulos</surname><given-names>I</given-names></name><name><surname>Xenikakis</surname><given-names>M</given-names></name><name><surname>Papathanasiou</surname><given-names>A</given-names></name><name><surname>Koulenti</surname><given-names>D</given-names></name><name><surname>Blot</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Clinical sepsis phenotypes in critically ill patients</article-title>. <source>Microorganisms</source> (<year>2023</year>) <volume>11</volume>(<issue>9</issue>). doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/microorganisms11092165</pub-id>
</mixed-citation></ref><ref id="B135"><label>135</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Madushani</surname><given-names>R</given-names></name><name><surname>Patel</surname><given-names>V</given-names></name><name><surname>Loftus</surname><given-names>T</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>HJ</given-names></name><name><surname>Velez</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Early biomarker signatures in surgical sepsis</article-title>. <source>J Surg Res</source> (<year>2022</year>) <volume>277</volume>:<page-range>372&#x02013;83</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jss.2022.04.052</pub-id>
</mixed-citation></ref><ref id="B136"><label>136</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baek</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kwon</surname><given-names>YS</given-names></name></person-group>. <article-title>Cluster analysis integrating age and body temperature for mortality in patients with sepsis: A multicenter retrospective study</article-title>. <source>Sci Rep</source> (<year>2022</year>) <volume>12</volume>(<issue>1</issue>):<fpage>1090</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41598-022-05088-z</pub-id>
<pub-id pub-id-type="pmid">35058521</pub-id>
</mixed-citation></ref><ref id="B137"><label>137</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thomas-Ruddel</surname><given-names>DO</given-names></name><name><surname>Hoffmann</surname><given-names>P</given-names></name><name><surname>Schwarzkopf</surname><given-names>D</given-names></name><name><surname>Scheer</surname><given-names>C</given-names></name><name><surname>Bach</surname><given-names>F</given-names></name><name><surname>Komann</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Fever and hypothermia represent two populations of sepsis patients and are associated with outside temperature</article-title>. <source>Crit Care (London England)</source> (<year>2021</year>) <volume>25</volume>(<issue>1</issue>):<fpage>368</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s13054-021-03776-2</pub-id>
</mixed-citation></ref><ref id="B138"><label>138</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matthay</surname><given-names>MA</given-names></name><name><surname>McAuley</surname><given-names>DF</given-names></name><name><surname>Ware</surname><given-names>LB</given-names></name></person-group>. <article-title>Clinical trials in acute respiratory distress syndrome: Challenges and opportunities</article-title>. <source>Lancet Respir Med</source> (<year>2017</year>) <volume>5</volume>(<issue>6</issue>):<page-range>524&#x02013;34</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S2213-2600(17)30188-1</pub-id>
</mixed-citation></ref><ref id="B139"><label>139</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reddy</surname><given-names>K</given-names></name><name><surname>Sinha</surname><given-names>P</given-names></name><name><surname>O'Kane</surname><given-names>CM</given-names></name><name><surname>Gordon</surname><given-names>AC</given-names></name><name><surname>Calfee</surname><given-names>CS</given-names></name><name><surname>McAuley</surname><given-names>DF</given-names></name></person-group>. <article-title>Subphenotypes in critical care: Translation into clinical practice</article-title>. <source>Lancet Respir Med</source> (<year>2020</year>) <volume>8</volume>(<issue>6</issue>):<page-range>631&#x02013;43</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S2213-2600(20)30124-7</pub-id>
</mixed-citation></ref><ref id="B140"><label>140</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sinha</surname><given-names>P</given-names></name><name><surname>Calfee</surname><given-names>CS</given-names></name></person-group>. <article-title>Phenotypes in acute respiratory distress syndrome: Moving towards precision medicine</article-title>. <source>Curr Opin Crit Care</source> (<year>2019</year>) <volume>25</volume>(<issue>1</issue>):<fpage>12</fpage>&#x02013;<lpage>20</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/MCC.0000000000000571</pub-id>
<pub-id pub-id-type="pmid">30531367</pub-id>
</mixed-citation></ref><ref id="B141"><label>141</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Famous</surname><given-names>KR</given-names></name><name><surname>Delucchi</surname><given-names>K</given-names></name><name><surname>Ware</surname><given-names>LB</given-names></name><name><surname>Kangelaris</surname><given-names>KN</given-names></name><name><surname>Liu</surname><given-names>KD</given-names></name><name><surname>Thompson</surname><given-names>BT</given-names></name><etal/></person-group>. <article-title>Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy</article-title>. <source>Am J Respir Crit Care Med</source> (<year>2017</year>) <volume>195</volume>(<issue>3</issue>):<page-range>331&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1164/rccm.201603-0645OC</pub-id>
</mixed-citation></ref><ref id="B142"><label>142</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Calfee</surname><given-names>CS</given-names></name><name><surname>Delucchi</surname><given-names>KL</given-names></name><name><surname>Sinha</surname><given-names>P</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name><name><surname>Hackett</surname><given-names>J</given-names></name><name><surname>Shankar-Hari</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: Secondary analysis of a randomised controlled trial</article-title>. <source>Lancet Respir Med</source> (<year>2018</year>) <volume>6</volume>(<issue>9</issue>):<page-range>691&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S2213-2600(18)30177-2</pub-id>
</mixed-citation></ref><ref id="B143"><label>143</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sinha</surname><given-names>P</given-names></name><name><surname>Furfaro</surname><given-names>D</given-names></name><name><surname>Cummings</surname><given-names>MJ</given-names></name><name><surname>Abrams</surname><given-names>D</given-names></name><name><surname>Delucchi</surname><given-names>K</given-names></name><name><surname>Maddali</surname><given-names>MV</given-names></name><etal/></person-group>. <article-title>Latent class analysis reveals covid-19-Related acute respiratory distress syndrome subgroups with differential responses to corticosteroids</article-title>. <source>Am J Respir Crit Care Med</source> (<year>2021</year>) <volume>204</volume>(<issue>11</issue>):<page-range>1274&#x02013;85</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1164/rccm.202105-1302OC</pub-id>
</mixed-citation></ref><ref id="B144"><label>144</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sinha</surname><given-names>P</given-names></name><name><surname>Delucchi</surname><given-names>KL</given-names></name><name><surname>Thompson</surname><given-names>BT</given-names></name><name><surname>McAuley</surname><given-names>DF</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name><name><surname>Calfee</surname><given-names>CS</given-names></name><etal/></person-group>. <article-title>Latent class analysis of ards subphenotypes: A secondary analysis of the statins for acutely injured lungs from sepsis (Sails) study</article-title>. <source>Intensive Care Med</source> (<year>2018</year>) <volume>44</volume>(<issue>11</issue>):<page-range>1859&#x02013;69</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00134-018-5378-3</pub-id>
</mixed-citation></ref><ref id="B145"><label>145</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sinha</surname><given-names>P</given-names></name><name><surname>Kerchberger</surname><given-names>VE</given-names></name><name><surname>Willmore</surname><given-names>A</given-names></name><name><surname>Chambers</surname><given-names>J</given-names></name><name><surname>Zhuo</surname><given-names>H</given-names></name><name><surname>Abbott</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Identifying molecular phenotypes in sepsis: An analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials</article-title>. <source>Lancet Respir Med</source> (<year>2023</year>) <volume>11</volume>(<issue>11</issue>):<page-range>965&#x02013;74</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S2213-2600(23)00237-0</pub-id>
</mixed-citation></ref><ref id="B146"><label>146</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Evrard</surname><given-names>B</given-names></name><name><surname>Sinha</surname><given-names>P</given-names></name><name><surname>Delucchi</surname><given-names>K</given-names></name><name><surname>Hendrickson</surname><given-names>CM</given-names></name><name><surname>Kangelaris</surname><given-names>KN</given-names></name><name><surname>Liu</surname><given-names>KD</given-names></name><etal/></person-group>. <article-title>Causes and attributable fraction of death from ards in inflammatory phenotypes of sepsis</article-title>. <source>Crit Care (London England)</source> (<year>2024</year>) <volume>28</volume>(<issue>1</issue>):<fpage>164</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s13054-024-04943-x</pub-id>
</mixed-citation></ref><ref id="B147"><label>147</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van Amstel</surname><given-names>RBE</given-names></name><name><surname>Bartek</surname><given-names>B</given-names></name><name><surname>Vlaar</surname><given-names>APJ</given-names></name><name><surname>Gay</surname><given-names>E</given-names></name><name><surname>van Vught</surname><given-names>LA</given-names></name><name><surname>Cremer</surname><given-names>OL</given-names></name><etal/></person-group>. <article-title>Temporal transitions of the hyperinflammatory and hypoinflammatory phenotypes in critical illness</article-title>. <source>Am J Respir Crit Care Med</source> (<year>2024</year>). doi:&#x000a0;<pub-id pub-id-type="doi">10.1164/rccm.202406-1241OC</pub-id>
</mixed-citation></ref><ref id="B148"><label>148</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Russell</surname><given-names>JA</given-names></name><name><surname>Walley</surname><given-names>KR</given-names></name><name><surname>Singer</surname><given-names>J</given-names></name><name><surname>Gordon</surname><given-names>AC</given-names></name><name><surname>Hebert</surname><given-names>PC</given-names></name><name><surname>Cooper</surname><given-names>DJ</given-names></name><etal/></person-group>. <article-title>Vasopressin versus norepinephrine infusion in patients with septic shock</article-title>. <source>N Engl J Med</source> (<year>2008</year>) <volume>358</volume>(<issue>9</issue>):<page-range>877&#x02013;87</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMoa067373</pub-id>
</mixed-citation></ref><ref id="B149"><label>149</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Neyton</surname><given-names>LPA</given-names></name><name><surname>Sinha</surname><given-names>P</given-names></name><name><surname>Sarma</surname><given-names>A</given-names></name><name><surname>Mick</surname><given-names>E</given-names></name><name><surname>Kalantar</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Host and microbe blood metagenomics reveals key pathways characterizing critical illness phenotypes</article-title>. <source>Am J Respir Crit Care Med</source> (<year>2024</year>) <volume>209</volume>(<issue>7</issue>):<page-range>805&#x02013;15</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1164/rccm.202308-1328OC</pub-id>
</mixed-citation></ref><ref id="B150"><label>150</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Goyal</surname><given-names>H</given-names></name><name><surname>Mo</surname><given-names>L</given-names></name><name><surname>Hong</surname><given-names>Y</given-names></name></person-group>. <article-title>Identification of subclasses of sepsis that showed different clinical outcomes and responses to amount of fluid resuscitation: A latent profile analysis</article-title>. <source>Crit Care (London England)</source> (<year>2018</year>) <volume>22</volume>(<issue>1</issue>):<fpage>347</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s13054-018-2279-3</pub-id>
</mixed-citation></ref><ref id="B151"><label>151</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shald</surname><given-names>EA</given-names></name><name><surname>Erdman</surname><given-names>MJ</given-names></name><name><surname>Ferreira</surname><given-names>JA</given-names></name></person-group>. <article-title>Impact of clinical sepsis phenotypes on mortality and fluid status in critically ill patients</article-title>. <source>Shock</source> (<year>2022</year>) <volume>57</volume>(<issue>1</issue>):<fpage>57</fpage>&#x02013;<lpage>62</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/SHK.0000000000001864</pub-id>
<pub-id pub-id-type="pmid">34559746</pub-id>
</mixed-citation></ref><ref id="B152"><label>152</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ma</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>F</given-names></name><name><surname>Liao</surname><given-names>X</given-names></name><name><surname>Xiu</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Individualized resuscitation strategy for septic shock formalized by finite mixture modeling and dynamic treatment regimen</article-title>. <source>Crit Care (London England)</source> (<year>2021</year>) <volume>25</volume>(<issue>1</issue>):<fpage>243</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s13054-021-03682-7</pub-id>
</mixed-citation></ref><ref id="B153"><label>153</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sinha</surname><given-names>P</given-names></name><name><surname>Calfee</surname><given-names>CS</given-names></name><name><surname>Cherian</surname><given-names>S</given-names></name><name><surname>Brealey</surname><given-names>D</given-names></name><name><surname>Cutler</surname><given-names>S</given-names></name><name><surname>King</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with covid-19: A prospective observational study</article-title>. <source>Lancet Respir Med</source> (<year>2020</year>) <volume>8</volume>(<issue>12</issue>):<page-range>1209&#x02013;18</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S2213-2600(20)30366-0</pub-id>
</mixed-citation></ref><ref id="B154"><label>154</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kotsaki</surname><given-names>A</given-names></name><name><surname>Pickkers</surname><given-names>P</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><name><surname>Calandra</surname><given-names>T</given-names></name><name><surname>Lupse</surname><given-names>M</given-names></name><name><surname>Wiersinga</surname><given-names>WJ</given-names></name><etal/></person-group>. <article-title>Immunosep (Personalised immunotherapy in sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: Study protocol</article-title>. <source>BMJ Open</source> (<year>2022</year>) <volume>12</volume>(<issue>12</issue>):<fpage>e067251</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1136/bmjopen-2022-067251</pub-id>
</mixed-citation></ref><ref id="B155"><label>155</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ates</surname><given-names>HC</given-names></name><name><surname>Alshanawani</surname><given-names>A</given-names></name><name><surname>Hagel</surname><given-names>S</given-names></name><name><surname>Cotta</surname><given-names>MO</given-names></name><name><surname>Roberts</surname><given-names>JA</given-names></name><name><surname>Dincer</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Unraveling the impact of therapeutic drug monitoring <italic>Via</italic> machine learning for patients with sepsis</article-title>. <source>Cell Rep Med</source> (<year>2024</year>) <volume>5</volume>(<issue>8</issue>):<elocation-id>101681</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.xcrm.2024.101681</pub-id>
<pub-id pub-id-type="pmid">39127039</pub-id>
</mixed-citation></ref><ref id="B156"><label>156</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Agullo</surname><given-names>L</given-names></name><name><surname>Aguado</surname><given-names>I</given-names></name><name><surname>Muriel</surname><given-names>J</given-names></name><name><surname>Margarit</surname><given-names>C</given-names></name><name><surname>Gomez</surname><given-names>A</given-names></name><name><surname>Escorial</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Pharmacogenetic guided opioid therapy improves chronic pain outcomes and comorbid mental health: A randomized, double-blind, controlled study</article-title>. <source>Int J Mol Sci</source> (<year>2023</year>) <volume>24</volume>(<issue>13</issue>). doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijms241310754</pub-id>
</mixed-citation></ref><ref id="B157"><label>157</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cummings</surname><given-names>MJ</given-names></name><name><surname>Bakamutumaho</surname><given-names>B</given-names></name><name><surname>Tomoiaga</surname><given-names>AS</given-names></name><name><surname>Owor</surname><given-names>N</given-names></name><name><surname>Jain</surname><given-names>K</given-names></name><name><surname>Price</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>A transcriptomic classifier model identifies high-risk endotypes in a prospective study of sepsis in uganda</article-title>. <source>Crit Care Med</source> (<year>2024</year>) <volume>52</volume>(<issue>3</issue>):<page-range>475&#x02013;82</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/CCM.0000000000006023</pub-id>
</mixed-citation></ref><ref id="B158"><label>158</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>DeMerle</surname><given-names>KM</given-names></name><name><surname>Angus</surname><given-names>DC</given-names></name><name><surname>Baillie</surname><given-names>JK</given-names></name><name><surname>Brant</surname><given-names>E</given-names></name><name><surname>Calfee</surname><given-names>CS</given-names></name><name><surname>Carcillo</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Sepsis subclasses: A framework for development and interpretation</article-title>. <source>Crit Care Med</source> (<year>2021</year>) <volume>49</volume>(<issue>5</issue>):<page-range>748&#x02013;59</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/CCM.0000000000004842</pub-id>
</mixed-citation></ref><ref id="B159"><label>159</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goligher</surname><given-names>EC</given-names></name><name><surname>Lawler</surname><given-names>PR</given-names></name><name><surname>Jensen</surname><given-names>TP</given-names></name><name><surname>Talisa</surname><given-names>V</given-names></name><name><surname>Berry</surname><given-names>LR</given-names></name><name><surname>Lorenzi</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Heterogeneous treatment effects of therapeutic-dose heparin in patients hospitalized for covid-19</article-title>. <source>Jama</source> (<year>2023</year>) <volume>329</volume>(<issue>13</issue>):<page-range>1066&#x02013;77</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1001/jama.2023.3651</pub-id>
</mixed-citation></ref><ref id="B160"><label>160</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kent</surname><given-names>DM</given-names></name><name><surname>Paulus</surname><given-names>JK</given-names></name><name><surname>van Klaveren</surname><given-names>D</given-names></name><name><surname>D'Agostino</surname><given-names>R</given-names></name><name><surname>Goodman</surname><given-names>S</given-names></name><name><surname>Hayward</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>The predictive approaches to treatment effect heterogeneity (Path) statement</article-title>. <source>Ann Intern Med</source> (<year>2020</year>) <volume>172</volume>(<issue>1</issue>):<fpage>35</fpage>&#x02013;<lpage>45</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.7326/M18-3667</pub-id>
<pub-id pub-id-type="pmid">31711134</pub-id>
</mixed-citation></ref><ref id="B161"><label>161</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aldrighetti</surname><given-names>CM</given-names></name><name><surname>Niemierko</surname><given-names>A</given-names></name><name><surname>Van Allen</surname><given-names>E</given-names></name><name><surname>Willers</surname><given-names>H</given-names></name><name><surname>Kamran</surname><given-names>SC</given-names></name></person-group>. <article-title>Racial and ethnic disparities among participants in precision oncology clinical studies</article-title>. <source>JAMA Netw Open</source> (<year>2021</year>) <volume>4</volume>(<issue>11</issue>):<fpage>e2133205</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.33205</pub-id>
<pub-id pub-id-type="pmid">34748007</pub-id>
</mixed-citation></ref><ref id="B162"><label>162</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cadario</surname><given-names>R</given-names></name><name><surname>Longoni</surname><given-names>C</given-names></name><name><surname>Morewedge</surname><given-names>CK</given-names></name></person-group>. <article-title>Understanding, explaining, and utilizing medical artificial intelligence</article-title>. <source>Nat Hum Behav</source> (<year>2021</year>) <volume>5</volume>(<issue>12</issue>):<page-range>1636&#x02013;42</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41562-021-01146-0</pub-id>
</mixed-citation></ref><ref id="B163"><label>163</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>He</surname><given-names>J</given-names></name><name><surname>Baxter</surname><given-names>SL</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name></person-group>. <article-title>The practical implementation of artificial intelligence technologies in medicine</article-title>. <source>Nat Med</source> (<year>2019</year>) <volume>25</volume>(<issue>1</issue>):<page-range>30&#x02013;6</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41591-018-0307-0</pub-id>
</mixed-citation></ref><ref id="B164"><label>164</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Flores</surname><given-names>C</given-names></name><name><surname>Villar</surname><given-names>J</given-names></name></person-group>. <article-title>The road to precision medicine in sepsis: Blood transcriptome endotypes</article-title>. <source>Lancet Respir Med</source> (<year>2017</year>) <volume>5</volume>(<issue>10</issue>):<page-range>767&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S2213-2600(17)30297-7</pub-id>
</mixed-citation></ref><ref id="B165"><label>165</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srdic</surname><given-names>T</given-names></name><name><surname>Durasevic</surname><given-names>S</given-names></name><name><surname>Lakic</surname><given-names>I</given-names></name><name><surname>Ruzicic</surname><given-names>A</given-names></name><name><surname>Vujovic</surname><given-names>P</given-names></name><name><surname>Jevdovic</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>From molecular mechanisms to clinical therapy: Understanding sepsis-induced multiple organ dysfunction</article-title>. <source>Int J Mol Sci</source> (<year>2024</year>) <volume>25</volume>(<issue>14</issue>). doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijms25147770</pub-id>
</mixed-citation></ref><ref id="B166"><label>166</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tang</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>XL</given-names></name><name><surname>Xu</surname><given-names>LY</given-names></name><name><surname>Zhang</surname><given-names>JN</given-names></name><name><surname>Ao</surname><given-names>H</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name></person-group>. <article-title>Endothelial dysfunction: Pathophysiology and therapeutic targets for sepsis-induced multiple organ dysfunction syndrome</article-title>. <source>Biomedicine Pharmacotherapy = Biomedecine Pharmacotherapie</source> (<year>2024</year>) <volume>178</volume>:<elocation-id>117180</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.biopha.2024.117180</pub-id>
<pub-id pub-id-type="pmid">39068853</pub-id>
</mixed-citation></ref><ref id="B167"><label>167</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Delucchi</surname><given-names>K</given-names></name><name><surname>Famous</surname><given-names>KR</given-names></name><name><surname>Ware</surname><given-names>LB</given-names></name><name><surname>Parsons</surname><given-names>PE</given-names></name><name><surname>Thompson</surname><given-names>BT</given-names></name><name><surname>Calfee</surname><given-names>CS</given-names></name><etal/></person-group>. <article-title>Stability of ards subphenotypes over time in two randomised controlled trials</article-title>. <source>Thorax</source> (<year>2018</year>) <volume>73</volume>(<issue>5</issue>):<page-range>439&#x02013;45</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1136/thoraxjnl-2017-211090</pub-id>
</mixed-citation></ref></ref-list></back></article>